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Abstract
Daxx, a multifunctional protein with a diverse set of proposed functions, is ubiquitously expressed and
highly conserved through evolution. A primarily nuclear protein, Daxx is able to regulate apoptosis,
transcription, and cellular proliferation. Despite many studies into the function of Daxx, its precise role in
the cell remains enigmatic. Herein, evidence is presented to expand upon the known anti-apoptotic
function of Daxx, to establish Daxx as a novel molecular chaperone, and to further its repertoire of
transcriptional targets. As an apoptotic inhibitor, Daxx is known to regulate p53 by stabilizing its main
negative regulator, Mdm2, via formation of a ternary complex between Daxx, Mdm2, and Hausp. The
present study reveals that DNA damage-induced phosphorylation of Daxx is an important step in the
disruption of the Daxx-Mdm2-Hausp complex, allowing for p53 activation. A novel activity for Daxx is
presented whereby it is able to modulate protein folding in vitro and in vivo. Daxx can refold and reactivate
denatured substrates using its paired amphipathic helical and acid-rich domains. This finding was
extended to p53, where Daxx was able to solubilize misfolded p53 both in vitro and in vivo. Further, this
finding may provide a biochemical rationale as to the varied functionality of Daxx in the cell. Finally, a
novel transcriptional target, Cdk6, is described for Daxx. Microarray analysis indicated that Cdk6 is a
strongly downregulated gene upon Daxx silencing. Depletion of Daxx in various cancer and primary cell
lines led to a decrease in Cdk6 protein levels. Additionally, Daxx can affect transcription of Cdk6, and
chromatin immunoprecipitation reveals that Daxx binds to the Cdk6 promoter. Together, these results
indicate that Daxx has potential functional plasticity and is involved in an array of cellular functions; in
fact, cellular homeostasis relies on the proper execution of multiple biological processes. Elucidation of
the biology of Daxx would not only provide insight into the regulation of these processes, but may also
establish Daxx as a relevant therapeutic target.
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ABSTRACT
THE MULTIFUNCTIONAL PROTEIN DAXX: STUDIES OF ITS BIOLOGY AND REGULATION,
AND DISCOVERY OF A NOVEL FUNCTION
Trisha Agrawal
Xiaolu Yang, PhD

Daxx, a multifunctional protein with a diverse set of proposed functions, is
ubiquitously expressed and highly conserved through evolution. A primarily nuclear
protein, Daxx is able to regulate apoptosis, transcription, and cellular proliferation.
Despite many studies into the function of Daxx, its precise role in the cell remains
enigmatic. Herein, evidence is presented to expand upon the known anti-apoptotic
function of Daxx, to establish Daxx as a novel molecular chaperone, and to further its
repertoire of transcriptional targets. As an apoptotic inhibitor, Daxx is known to regulate
p53 by stabilizing its main negative regulator, Mdm2, via formation of a ternary complex
between Daxx, Mdm2, and Hausp. The present study reveals that DNA damage-induced
phosphorylation of Daxx is an important step in the disruption of the Daxx-Mdm2-Hausp
complex, allowing for p53 activation. A novel activity for Daxx is presented whereby it is
able to modulate protein folding in vitro and in vivo. Daxx can refold and reactivate
denatured substrates using its paired amphipathic helical and acid-rich domains. This
finding was extended to p53, where Daxx was able to solubilize misfolded p53 both in
vitro and in vivo. Further, this finding may provide a biochemical rationale as to the
varied functionality of Daxx in the cell. Finally, a novel transcriptional target, Cdk6, is
described for Daxx. Microarray analysis indicated that Cdk6 is a strongly downregulated
gene upon Daxx silencing. Depletion of Daxx in various cancer and primary cell lines led
to a decrease in Cdk6 protein levels. Additionally, Daxx can affect transcription of Cdk6,
vi

and chromatin immunoprecipitation reveals that Daxx binds to the Cdk6 promoter.
Together, these results indicate that Daxx has potential functional plasticity and is
involved in an array of cellular functions; in fact, cellular homeostasis relies on the proper
execution of multiple biological processes. Elucidation of the biology of Daxx would not
only provide insight into the regulation of these processes, but may also establish Daxx
as a relevant therapeutic target.
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CHAPTER 1: INTRODUCTION
Daxx
The multifunctional protein Daxx (death domain-associated protein) has been
implicated in apoptosis, transcription, and cellular proliferation. Despite extensive study
into its function, its precise role in the cell is unclear and encompasses a seemingly
divergent set of proposed activities. This dissertation aims to further understand the
biological role of Daxx and the following section will give an overview regarding the
structure, subcellular localization, and known functions of Daxx.
Discovery and Structure
Daxx was first identified by a yeast two-hybrid screen as an adaptor protein for
the intracellular portion of the death receptor, Fas (CD95/Apo-1), and potentiates Fasinduced apoptosis via the c-Jun N-terminal kinase (JNK) pathway (Yang, Khosravi-Far,
et al, 1997). Human Daxx is a protein of 740 amino acids and has no significant
homology to known proteins. It is ubiquitously expressed with especially high expression
in the testes (Kiriakidou, Driscoll, et al, 1997; Yang, Khosravi-Far, et al, 1997). Daxx is
poorly characterized at the structural level; however, among known domains it contains
two N-terminal paired amphipathic helical domains, a coiled-coil domain, an acid-rich
(D/E) domain, and a C-terminal Serine/Proline/Threonine-rich domain (Figure 1.1). Daxx
also contains two SUMO-interacting motifs (SIMs), one each within its N- and Cterminus, which are important for its subcellular localization and association with other
proteins (Escobar-Cabrera, Okon, et al, 2011; Lin, Huang, et al, 2006; Ryu, Chae, and
Kim, 2000; Santiago, Godsey, et al, 2009).

1

Figure 1.1. Schematic depicting structural domains within Daxx.
PAH – paired amphipathic helices; CC – coiled coil domain; D/E – acid-rich region;
S/P/T – serine/proline/threonine-rich region. Asterisks indicate SUMO-interacting motifs.
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Cellular Localization
Subsequent to its initial discovery as a cytoplasmic protein, many studies
emerged confirming the cytoplasmic localization of Daxx and validating its pro-apoptotic
function (Chang, Nishitoh, et al, 1998; Gongora, Stephan, et al, 2001; Ko, Kang, et al,
2001; Lalioti, Vergarajauregui, et al, 2002; Perlman, Schiemann, et al, 2001). In the
cytoplasm, Daxx associates with the apoptosis signaling kinase 1 (ASK1) and this
association can be inhibited by heat shock protein 27 (Hsp27) (Chang, Nishitoh, et al,
1998; Charette, Lavoie, et al, 2000; Ko, Kang, et al, 2001; Song, and Lee, 2003).
Despite evidence of Daxx being a pro-apoptotic protein residing mainly in the cytoplasm,
it later became clear that Daxx is predominantly a nuclear protein, which may be
translocated to the cytoplasm in response to certain stimuli; for example, FAS
stimulation and glucose deprivation (Lindsay, Giovinazzi, and Ishov, 2009; Song, and
Lee, 2004; Yang, Khosravi-Far, et al, 1997).

In the nucleus, Daxx localizes in promyelocytic leukemia-nuclear bodies (PMLNBs), macromolecular complexes that regulate a variety of cellular processes including
tumor suppression and transcriptional repression (Bernardi, and Pandolfi, 2007; Li, Leo,
et al, 2000; Torii, Egan, et al, 1999; Zhong, Salomoni, et al, 2000). An essential
component of PML-NBs is the PML protein, which when SUMOylated, is recognized by
the C-terminal SIM on Daxx and leads to the accumulation of Daxx at PML-NBs (Ishov,
Vladimirova, and Maul, 2004; Lin, Huang, et al, 2006). Daxx displays aberrant
localization in acute promyelocytic leukemia (APL) cells, where the PML-NB structure is
disrupted (Zhong, Salomoni, et al, 2000). Daxx recruitment to PML-NBs is important for
many of its functions including apoptotis and transcription (Li, Leo, et al, 2000; Torii,
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Egan, et al, 1999). For example, in PML -/- B-lymphocytes, apoptosis is impaired due to
the delocalization of Daxx from the PML-NBs (Zhong, Salomoni, et al, 2000).

In addition to its accumulation at PML-NBs, Daxx is localized to heterochromatin
in a cell cycle-dependent manner (Hollenbach, McPherson, et al, 2002; Ishov, Sotnikov,
et al, 1999; Ishov, Vladimirova, and Maul, 2004). This localization occurs via the
association of Daxx with the α-thalassemia/mental retardation syndrome protein (ATRX),
a putative member of the SNF2 family of ATP-dependent chromatin remodeling proteins
(Tang, Wu, et al, 2004; Xue, Gibbons, et al, 2003). The N-terminus of Daxx interacts
with ATRX and this association depends upon the phosphorylation of ATRX (Ishov,
Vladimirova, and Maul, 2004). Ishov, et al found that Daxx and ATRX associate at PMLNBs during most of interphase. Daxx then leaves the PML-NBs and is actively recruited
to heterochromatin during late S phase via association with phosphorylated ATRX and
loss of Daxx leads to prolongation of S phase of the cell cycle (Ishov, Vladimirova, and
Maul, 2004). Until recently, there was no explanation as to why Daxx would associate
with heterochromatin during such a short window of time during the cell cycle. The newly
discovered function of Daxx as a histone chaperone may shed light on this phenomenon
and will be discussed in a later section.

Function
Apoptosis
Daxx initially appeared to be a pro-apoptotic protein; however, several lines of
evidence indicate that Daxx may also have an anti-apoptotic function. Disruption of the
Daxx gene in mice leads to embryonic lethality before E8.5 (Michaelson, Bader, et al,
1999). Daxx -/- embryonic stem (ES) cells show higher rates of spontaneous apoptosis,
4

suggesting that Daxx has an anti-apoptotic role that is important during development.
Further, Daxx silencing in various cell lines sensitizes cells to apoptotic stimuli, verifying
Daxx as an important anti-apoptotic modulator (Chen, and Chen, 2003; Michaelson, and
Leder, 2003).

Additionally, research from our lab shows that Daxx has a critical role in
regulating the tumor suppressor p53 by stabilizing mouse double minute 2 (Mdm2), the
major p53 negative regulator (Tang, Qu, et al, 2006). Daxx forms a complex with Mdm2
and herpesvirus-associated ubiquitin-specific protease (Hausp) that serves to stabilize
Mdm2, leading to the ubiquitination and degradation of p53 (Figure 1.2). Upon DNA
damage, the Daxx-Mdm2-Hausp complex dissociates, resulting in Mdm2 degradation
and allowing for the activation of p53-mediated apoptosis. The disruption of this complex
is mediated by the protein kinase ATM (ataxia telangiectasia mutated); how ATM
mediates the dissociation of the complex is the focus of chapter two.

Transcriptional Regulation
Due to the localization of Daxx to the nucleus, and in particular heterochromatin,
several groups have focused their efforts on uncovering a possible role for Daxx in
transcriptional regulation. Daxx has a diverse array of binding partners and many of
these include transcription factors. Generally, Daxx is a transcriptional repressor as
shown by its ability to repress the activity of several transcription factors including Pax3,
ETS1, p53 and p73, NF-κB, CREB, glucocorticoid receptor, and HDAC2, among others
(Gostissa, Morelli, et al, 2004; Huang, Chang, et al, 2012; Kim, Park, and Um, 2003;
Lehembre, Muller, et al, 2001; Li, Leo, et al, 2000; Morozov, Massoll, et al, 2008; Park,
Lee, et al, 2007). The transcriptional repressive activities of Daxx have been linked to its
5

Figure 1.2. Illustration depicting role of Daxx in Mdm2 and p53 stability.
In unstressed cells, Daxx bridges the interaction between Hausp and Mdm2, preventing
Mdm2 ubiquitination. Upon induction of DNA damage, the complex dissociates leading
to Mdm2 degradation and p53-mediated apoptosis and p21 transcription.
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association with ATRX and its delocalization from PML-NBs (Newhart, Rafalska-Metcalf,
et al, 2012). PML can inhibit Daxx-mediated transcriptional repression via direct binding
to Daxx and by subsequent recruitment of Daxx to PML-NBs. In PML -/- cells, Daxx
forms aggregates around condensed chromatin, where it may exert its repressive
activities (Zhong, Salomoni, et al, 2000). Daxx can also activate transcription of a few
transcription factors, for example, Pax5 and HSF1, albeit under very specific cellular
conditions (Boellmann, Guettouche, et al, 2004; Emelyanov, Kovac, et al, 2002).

Related to its activity as a transcriptional regulator, recent studies have
implicated Daxx as a histone chaperone for the histone 3 (H3) variant, H3.3 (Drane,
Ouararhni, et al, 2010; Elsaesser, and Allis, 2010; Lewis, Elsaesser, et al, 2010). Unlike
the other H3 variants, H3.1 and H3.2, H3.3 is expressed throughout the cell cycle and is
incorporated in chromatin in a replication-independent manner (Elsaesser, Goldberg,
and Allis, 2010; Wu, Tsai, and Bonner, 1982). H3.3 is believed to be an important carrier
of genetic information and while it was initially found solely at euchromatin, it has been
shown to associate with regulatory elements and constitutive chromatin at telomeres
(Lewis, Elsaesser, et al, 2010; Salomoni, 2013). Prior to the discovery of Daxx as a
histone chaperone, the interaction between ATRX and H3.3 was considered to be
essential for the maintenance of telomere structural integrity (Wong, McGhie, et al,
2010). Subsequent to this, two groups independently found that Daxx also associates
specifically with H3.3 via the central domain of Daxx (Drane, Ouararhni, et al, 2010;
Goldberg, Banaszynski, et al, 2010; Lewis, Elsaesser, et al, 2010). In accordance with
its subcellular localization, Daxx was found in both cytoplasmic and nuclear H3.3
complexes. While Daxx alone was able to assemble chromatin in vitro, the deposition of
H3.3 onto telomeres was dependent upon the formation of the Daxx-ATRX complex.
7

This Daxx-ATRX-dependent targeting of H3.3 to telomeres appears to suppress
transcription over telomeric repeats in ES cells (Goldberg, Banaszynski, et al, 2010).
Conversely, the deposition of H3.3 on pericentric heterochromatin by Daxx and ATRX
leads to a greater abundance of mRNA transcripts at these regions (Drane, Ouararhni,
et al, 2010). The role of H3.3 deposition is unclear, but the function of Daxx as a H3.3
chaperone provides a potential mechanism for its transcriptional regulatory activity.
Indeed, a recent study shows that in neuronal cells, the deposition of H3.3 at a subset of
immediate early genes (IEGs; Bdnf Exon IV, c-Fos, Egr2, and Dusp6) relies mainly on
Daxx, leading to increased transcriptional induction of these genes (Michod, Bartesaghi,
et al, 2012). It is clear that Daxx has the ability to regulate transcription but it is still
nebulous if this regulation is inhibitory or activating. A novel transcriptional target of
Daxx, Cdk6, will be explored in chapter four.

Cellular Proliferation and Cancer

Due to the interaction of Daxx with multiple proteins and the varying
consequences of these interactions, it is plausible that Daxx has proliferative effects that
may be mediated via its influence on apoptosis, transcription, p53 regulation, or histone
chaperone activity. These effects may regulate the promotion of cancer and/or
tumorigenesis. In fact, many groups have found that Daxx is involved in cellular
proliferation and in turn, cancer progression. As previously discussed, Daxx can stabilize
Mdm2 leading to the ubiquitination and degradation of p53. Depletion of Daxx in cells
leads to greater apoptosis in an Mdm2- and p53-dependent manner (Tang, Qu, et al,
2006). This observation has led other groups to identify Daxx as an important modulator
of p53 in cancer. Two studies from the same group indicate that Daxx is important for
ovarian cancer progression (Pan, Yi, et al, 2013; Pan, Zhou, et al, 2013). They reported
8

that Daxx mRNA and protein levels were overexpressed in ovarian cancer cells lines
and ectopic expression of Daxx led to increased ovarian cancer cell proliferation,
migration, colony formation, and chemoresistance; depletion of Daxx had the converse
effect. Additionally, transplantation of stable cells overexpressing Daxx into nude mice
was capable of forming metastatic tumors. Daxx silencing led to enhanced senescence
in mouse ovary surface epithelial (mOSE) cells in a p53/p21-dependent manner. In
another study using pediatric acute lymphoblastic leukemia (ALL) cells, a
pharmacological intervention was used to disrupt the Daxx-Mdm2-Hausp complex. The
group found that Berberine, a potential herbal chemotherapeutic, was able to decrease
Daxx transcription and protein levels, which led to reduced formation of the Daxx-Mdm2Hausp complex. This allowed for p53 activation and greater cell death of the ALL cells
(Zhang, Gu, et al, 2010).

The role of Daxx as a histone chaperone has also proven to be important for
certain cancers, including pancreatic neuroendocrine tumors (PanNETs) and pediatric
glioblastoma multiforme (GBM) (de Wilde, Edil, et al, 2012; Zhang, Francois, et al,
2013). When the exome of primary PanNETs was sequenced, somatic mutations in the
genes encoding Daxx and ATRX were found in 42.6% of the PanNETs. There were
mutually exclusive mutations in Daxx and ATRX, consistent with their presumptive
cooperation in transcription and histone chaperone activity. Interestingly, patients with
mutations in Daxx or ATRX had prolonged survival rates compared to patients without
mutations in these genes (Jiao, Shi, et al, 2011). Due to the role of Daxx and ATRX in
chromatin remodeling at telomeres, Heaphy, et al examined the status of telomeres in
patients with PanNETs that contained mutations in Daxx or ATRX. A perfect correlation
between loss of ATRX or Daxx function and the presence of alternative lengthening of
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telomeres (ALT) was observed (Heaphy, de Wilde, et al, 2011). Further, mutations in
Daxx and ATRX have been found in cases of pediatric GBM. A recent study showed that
mutations in Daxx or ATRX were found in 31% of the tumor samples analyzed, and in
100% of samples that also harbored mutations in the gene that codes for H3.3, H3F3A
(Schwartzentruber, Korshunov, et al, 2012). Again, a mutation in Daxx or ATRX was
strongly correlated with the presence of the ALT phenotype (Schwartzentruber,
Korshunov, et al, 2012). Although a mechanism for how Daxx and ATRX cooperate to
cause ALT has not been proposed, it is logical to posit that their histone chaperone and
chromatin remodeling activities are intimately linked to this phenotype.

Daxx has also been implicated in a few scenarios of cancer using novel
pathways of action. One such instance is the interaction of Daxx with RAS-association
domain family protein 1A (Rassf1A). In human breast cancer cells with experimentally
reduced Daxx, the cells display resistance to taxol, a microtubule-destabilizing agent
commonly used as a chemotherapeutic. In Daxx-depleted cells, there is a prolonged
stabilization of cyclin B leading to faster progression through prophase but a lengthening
of prometaphase/metaphase, when Daxx and Rassf1A are found to interact. In cells that
respond to taxol therapy, taxol induces mitotic block creating micronucleated cells that
are incapable of proliferation. In Daxx- and Rassf1A-depleted cells, the accumulation of
cyclin B allows for cells to reenter mitosis after mitotic block is induced making them
resistant to taxol, whereas breast cancer cells expressing high levels of Daxx exhibit a
robust response to taxol (Giovinazzi, Lindsay, et al, 2012). Additionally, Daxx expression
is often upregulated in prostate cancer cells and is positively correlated with Gleason
score and metastasis. Daxx can induce chromosome instability in these cells via
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inhibition of the anaphase-promoting complex (APC), leading to chromosomal polyploidy
during prostate cancer development (Kwan, Lau, et al, 2013).

Scope of Dissertation

There is great ambiguity regarding the biology of Daxx in the cell. In this
dissertation, I examine three distinct functions of Daxx that further elucidate the various
processes in which Daxx is involved. First, I expand the previously found role of Daxx in
p53 regulation by finding that phosphorylation of Daxx by ATM upon DNA damage leads
to dissociation of the Daxx-Mdm2-Hausp complex in chapter two. Second, I uncover a
novel role for Daxx in protein folding, whereby Daxx is able to refold and recover the
activity of denatured substrates in chapter three. Finally, I briefly investigate if Daxx can
regulate the cell cycle via a specific cyclin-dependent kinase (Cdk), Cdk6, in chapter
four. The following sections of this chapter will provide brief introductions into the major
biological themes of each of these projects: the mutual regulation between Mdm2 and
p53, an overview of protein quality control in mammalian cells, and an outline of cell
cycle progression.

The Mdm2-p53 Feedback Loop
The tumor suppressor p53 is one of the most extensively studied proteins as
evidenced by the sheer number (over 60,000 as of 2012) of publications centering on its
function and regulation. Its study has proven to be invaluable as more than 50% of
human tumors harbor mutations in p53 itself or p53 effector proteins (Vogelstein, Lane,
and Levine, 2000). Deletion of p53 in mice does not lead to embryonic lethality or
developmental defects but does predispose the mice to spontaneous lymphomas and
sarcomas by 2.5 months of age, leading to death by 6 months of age (Donehower,
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Harvey, et al, 1992). 95% of malignant mutations of p53 are missense mutations found
in the DNA-binding domain (DBD) (Greenblatt, Bennett, et al, 1994; Pavletich,
Chambers, and Pabo, 1993). A proportion of these mutations lead to structural instability
of p53 (Ang, Joerger, et al, 2006). It is known that mutant p53 often acts as a dominantnegative due to the formation of mixed tetramers, which contain both wild-type and
mutant p53, abrogating the transcriptional effects of wild-type p53 (Chan, Siu, et al,
2004). A recent study suggests that structurally destabilized mutant p53 has greater
aggregation propensity, which induces misfolding in wild-type p53 and thereby
decreases the concentration of functional p53 in the cell (Xu, Reumers, et al, 2011).
In the cell, p53 levels are tightly controlled by its continuous ubiquitination and
degradation, a process predominantly mediated by Mdm2 (Momand, Wu, and Dasgupta,
2000). In response to various stresses, such as DNA damage and oncogene activation,
p53 is activated, which leads to the transcription of anti-proliferative genes. These
effector proteins include pro-apoptotic (Bax and Apaf-1, e.g.), cell cycle arrest (p21, e.g.)
or cellular senescence (p21 and PML, e.g.) promoting factors (Figure 1.3) (Vogelstein,
Lane, and Levine, 2000). p53 is heavily post-translationally modified upon its activation,
leading to conformational changes within the protein allowing for it to become a
transcriptional activator. p53 is acetylated, methylated, ubiquitinated, and SUMOylated.
The extent and type of modification depends on the cellular context (Gu, and Zhu, 2012).
The N-terminus of p53 is extensively phosphorylated, including its phosphorylation by
ATM and Chk2 at Ser15 and Ser20, respectively, upon DNA damage (Banin, Moyal, et
al, 1998; Hirao, Kong, et al, 2000). One of the most important modifications that occurs
on p53 is Mdm2-mediated ubiquitination (Gu, and Zhu, 2012).
Mdm2 is an E3 ubiquitin ligase not only for p53, but also for itself (Fang, Jensen,
et al, 2000; Fuchs, Adler, et al, 1998). The Mdm2 gene was originally cloned from the
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Figure 1.3. The p53 response.
Upon the induction of various stress signals, p53 levels are stabilized leading to the
activation of different downstream regulators. The net effect of these regulators is to
inhibit cell growth, ultimately preventing tumorigenesis. Reproduced with permission
(Vousden, and Lu, 2002).
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3T3-DM transformed mouse cell line, where it was gene-amplified on double-minute
chromosomes (Fakharzadeh, Trusko, and George, 1991). Ensuing discoveries
established the importance of Mdm2 as a p53 negative regulator not only via its ubiquitin
ligase activity, but also due to its direct binding to the N-terminus of p53 and subsequent
inhibition of p53 transcriptional activity (Chen, Marechal, and Levine, 1993; Kubbutat,
Jones, and Vousden, 1997; Momand, Zambetti, et al, 1992). In an unstressed cell,
Mdm2 associates with p53, targeting it for degradation (Figure 1.4). Upon the induction
of DNA damage, for example, the Mdm2-p53 complex is disrupted through the
accumulation

of

post-translational

modifications

on

both

p53

and

Mdm2.

Phosphorylation of Mdm2 by ATM inhibits its E3 ligase activity due to the disruption of
higher-order Mdm2 oligomers that are necessary for its activity (Cheng, Chen, et al,
2009). The dissociation of p53 from Mdm2 allows p53 to avoid degradation and act as a
transcriptional activator. Intriguingly, the Mdm2 gene is also a direct transcriptional target
of p53, whereby Mdm2 levels increase in response to p53 transactivation (Figure 1.4)
(Barak, Juven, et al, 1993; Picksley, and Lane, 1993; Wu, and Levine, 1997). The
importance of the negative feedback loop between Mdm2 and p53 is underscored by the
finding that though mdm2 -/- mice are embryonic lethal, this lethality can be rescued via
simultaneous deletion of the p53 gene (Jones, Roe, et al, 1995; Montes de Oca Luna,
Wagner, and Lozano, 1995). This finding indicates that the main role of Mdm2 during
development is to restrain the apoptotic activity of p53 and that a hyperactive p53 in
incompatible with animal survival. Additionally, 7% of human tumors have gene
amplification or aberrant expression of Mdm2 and Mdm2 overexpression and p53
mutations are generally mutually exclusive (Wade, Li, and Wahl, 2013). It is clear that
the mutual regulation of p53 and Mdm2 is critical for cell viability as perturbations in this
system can lead to human malignancies. Understanding the critical regulators of
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Figure 1.4. The p53-Mdm2 feedback loop.
In an unstressed cell, Mdm2 targets p53 for degradation in the 26S proteasome via
ubiquitination. Upon the induction of stress, p53 is activated and transactivates Mdm2.
Mdm2 then ubiquitinates p53 preventing further gene transactivation. This, in turn, forms
a feedback loop between Mdm2 and p53. Reproduced and modified with permission
(Murray-Zmijewski, Slee, and Lu, 2008).
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these two proteins is essential and will be the focus of chapter two.
Protein Quality Control
The proper functioning of the cell relies on correct protein folding. There are
approximately 20,000 proteins involved in the biological processes of the cell and for
most of these the acquisition of a three-dimensional structure is a requirement for
biological activity (Dobson, 2003). Protein folding in the cell can occur in various
compartments. For example, during translation of proteins from the ribosome, protein
folding occurs co-translationally as regions of the nascent polypeptide chain begin to fold
before synthesis of the entire protein (Hardesty, and Kramer, 2001). Other proteins may
undergo the majority of their folding in the cytoplasm after release from the ribosome,
while others may fold in specific compartments such as the endoplasmic reticulum (ER)
or mitochondria (Hartl, and Hayer-Hartl, 2002). During these folding processes, it is likely
that portions of a nascent polypeptide will be exposed in partially folded, aggregationprone states for considerable periods of time. Additionally, proteins folding during
translation or in other compartments will be subject to the crowded intracellular milieu,
strongly increasing the probability of non-native proteins to aggregate (Ellis, 2001; Ellis,
and Minton, 2006). Moreover, errors in protein folding naturally occur due to genetic
mutations or protein damage caused by cellular stress. Thus, the cell must maintain a
proteostasis network to contend with these issues as the proper folding of a protein is
not only important for its biological activity, but also for general cellular viability as the
failure of proteins to fold properly is associated with proteinopathies such as
neurodegenerative disorders, type 2 diabetes, cardiovascular disease, and cancer
(Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011; Morimoto, 2008; Taylor, Hardy,
and Fischbeck, 2002).
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How proteins achieve their native conformations has been the subject of
research for many decades. The possible conformations a protein can adopt are
astronomically large; thus, complex folding mechanisms are in place to promote the
burial of hydrophobic residues and prevent aggregation (Hartl, Bracher, and Hayer-Hartl,
2011; Zwanzig, Szabo, and Bagchi, 1992). Current theories suggest that competing
reactions of protein folding and aggregation exist in the cell and form a funnel-shaped
potential energy landscape (Figure 1.5) (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl,
2011; Kim, Hipp, et al, 2013). This theory postulates that there are few lower-energy,
native-like conformations that a protein can have and that a protein travels on a downhill
path toward a conformation of lowest energy (Dill, and MacCallum, 2012). As proteins
move toward the native state, they form intramolecular contacts that create kinetically
trapped intermediate conformations leading to free energy barriers that need to be
overcome to reach the more favorable, low energy state. If many proteins are folding
simultaneously in the same compartment, intermolecular contacts may form leading to
the formation of amorphous aggregates, oligomers, or amyloid fibrils. Often times, the
aggregated or fibrillar state may be most energetically favorable, though their formation
is largely restricted in vivo. However, they may persist during times of stress or protein
quality control failure (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011).
Due to the complexity and significance of protein folding, the cell contains an
elaborate protein quality control system to achieve proteostasis and maintain cellular
health. Protein quality control is executed using an extensive network of proteins, the
majority of which are molecular chaperones (Powers, Morimoto, et al, 2009). Although,
the amino acid sequence is sufficient to confer three-dimensional structure to a protein,
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Figure 1.5. Energy landscape of protein folding.
Competing reactions between protein folding and aggregation naturally occur while a
protein reaches its native structure. As proteins travel toward their native conformation,
they form kinetically trapped intermediates that need to traverse energy barriers to reach
their thermodynamically favorable conformation; steps made more efficient by molecular
chaperones. Aggregates may form when inappropriate intermolecular contacts form
during simultaneous folding of many proteins in the same compartments. In vivo, the
formation of these structures is generally restrained by molecular chaperones.
Reproduced with permission (Hartl, Bracher, and Hayer-Hartl, 2011).

18

many proteins require molecular chaperones to reach their native state efficiently
(Anfinsen, 1973; Hartl, 1996). A molecular chaperone is defined as a protein that
interacts with and helps another protein acquire its functionally active state without being
present in its final structure (Hartl, 1996). To achieve proteostasis, molecular
chaperones can promote the refolding of an aberrantly folded protein, send a misfolded
protein for degradation, or sequester the protein to specialized quality control
compartments (Figure 1.6) (Chen, Retzlaff, et al, 2011). For the purposes of this
dissertation, I will focus on molecular chaperones and their folding activities.
Molecular chaperones interact with unfolded or partially folded protein subunits,
for example, nascent chains emerging from the ribosome, where they participate in cotranslational folding (Frydman, Erdjument-Bromage, et al, 1999; Hartl, and Hayer-Hartl,
2002; Netzer, and Hartl, 1997). The expression of molecular chaperones is often
increased by cellular stress. Molecular chaperones can also stabilize non-native
conformations and facilitate correct folding of protein subunits via coupling of ATP
binding/hydrolysis to the folding process. In vivo, molecular chaperones strongly restrict
the formation of aggregates and increase the overall efficiency of the protein folding
process by reducing the probability of competing reactions, especially aggregation
(Figure 1.5) (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011).
One of the major classes of chaperones in the cells are the heat shock proteins
(Hsps), so named because their expression is often upregulated upon the induction of
cellular stress including heat shock, oxidative damage, and hypoxia, among others
(Santoro, 2000; Whitley, Goldberg, and Jordan, 1999). The Hsps are named according
to their molecular weight (in kDa): Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, and the small
Hsps (sHsps). The Hsps are involved in a multitude of protein quality control activities
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Figure 1.6. Chaperones and the proteostasis network.
The proteostasis network encompasses a large network of proteins, the majority of
which are molecular chaperones. The chaperones are necessary to fold newly
synthesized proteins, refold misfolded proteins, prevent protein aggregation, promote
disaggregation, and send misfolded proteins for degradation via the proteasome or
autophagy. Reproduced with permission (Hartl, Bracher, and Hayer-Hartl, 2011).
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including de novo protein folding, refolding of stress-denatured proteins, signal
transduction, and proteolytic degradation. The chaperones mainly involved in protein
folding and refolding are the Hsp40s, Hsp70s, Hsp90s, Hsp100s and the Hsp60s, which
are also known as chaperonins (Hartl, 1996; Hartl, Bracher, and Hayer-Hartl, 2011; Kim,
Hipp, et al, 2013).
The function of the Hsp70 family of chaperones in protein folding can be
described as the prevention of aggregation, the promotion of folding to the native state,
and the solubilization and refolding of misfolded proteins (Mayer, and Bukau, 2005).
The Hsp70 proteins have three main structural domains. The first is an N-terminal
ATPase domain, which binds ATP and hydrolyzes it to ADP, a process catalyzed via
association with Hsp40. The second is a substrate-binding domain that has affinity for
the exposed hydrophobic regions on peptide segments. By binding to the hydrophobic
patches on substrate molecules, Hsp70 and Hsp40 can prevent aggregation by blocking
inappropriate interactions between non-native structures. Interestingly, the surface
potential surrounding the substrate binding domain is negatively charged, which explains
the contribution of positive charges in peptides for the affinity of Hsp70. Finally, the Cterminal portion is rich in α-helical structures, acting as lid for the substrate binding
domain (Mayer, and Bukau, 2005). Hsp70 and Hsp40 can also assist non-native folding
intermediates to fold into their native structures; however, the mechanism as to how this
occurs is unclear (Mayer, and Bukau, 2005). Hsp70 also works in cooperation with the
Hsp60 (chaperonin) class of chaperones to mediate protein folding. Chaperonins are
large ring-like complexes that enclose substrates in their central cavity for folding
(Horwich, Fenton, et al, 2007). Hsp70 and the chaperonins work together to aid nascent
polypeptides in reaching their native structure; Hsp70 interacts with nascent
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polypeptides as they emerge from the ribosome while the chaperonins act downstream
to trap those substrates that escape the folding activity of Hsp70 (Frydman,
Nimmesgern, et al, 1994; Langer, Lu, et al, 1992). Recently, an intriguing property of
Hsp70 has emerged whereby, in an ATP-dependent manner, Hsp70 converts misfolded
substrates into unfolded intermediates, which are then able to refold to their native state
upon release from Hsp70. These results challenge the theory that Hsp70 chaperones
are able to fold proteins; rather, they point toward an unfolding function prior to
chaperone-independent refolding (Sharma, De los Rios, et al, 2010).
Despite the wealth of information regarding protein folding and misfolding, there
is little known about how protein aggregation is reversed in the cell. It is known that the
heat shock proteins can prevent aggregation, but very few possess disaggregation
activity. The chaperonin, specifically GroEL-GroES in bacteria, and the Hsp70/40
systems have demonstrated in vitro disaggregation and reactivation ability in very
specific cases using particular substrates: RNA polymerase (Skowyra, Georgopoulos,
and Zylicz, 1990; Ziemienowicz, Skowyra, et al, 1993), malate dehydrogenase (Veinger,
Diamant, et al, 1998) and glucose-6-phosphate dehydrogenase (Diamant, Ben-Zvi, et al,
2000). Most bacteria and eukaryotes including protozoa, fungi, and plants contain
homologs of the AAA+ ATPase, Hsp104, a member of the Hsp100 class of chaperones.
Hsp104 from yeast, in concert with Hsp70/40, can disaggregate and reactivate
chemically denatured proteins in vitro (Glover, and Lindquist, 1998; Goloubinoff, Mogk,
et al, 1999). Hsp104 also confers thermotolerance to yeast cells; a property related to its
ability to rescue misfolded or aggregated proteins (Sanchez, Taulien, et al, 1992).
Hsp104 can cooperate with mammalian Hsp70/40 for disaggregation indicating that
there is no species barrier between yeast Hsp104 and mammalian chaperones (Shorter,
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2011). Strikingly, there is no metazoan homolog for Hsp104. Thus, it remains unclear if
mammalian cells contain disaggregation abilities.
Recent studies have tried to determine if mammalian cells contain potent
disaggregation activity and if this activity can be attributed to a single protein. Valosincontaining protein (VCP or p97), a member of the AAA+ ATPase family, has emerged as
an attractive candidate. VCP is able to prevent the aggregation of denatured luciferase
both in vivo and in vitro and it can also assist in the suppression and clearance of protein
aggregates; however, its activity has not been clearly established (Kobayashi, Manno,
and Kakizuka, 2007; Song, Wang, and Li, 2007). Recently, an Hsp70-related protein,
Hsp110 has been shown to cooperate with Hsp70/40 in the mammalian cytosol to
disaggregate and reactivate aggregated GFP and luciferase (Mattoo, Sharma, et al,
2013; Shorter, 2011). These results established that Hsp110, Hsp70, and Hsp40
constitute an ATP-dependent disaggregase machinery that is active in the mammalian
cytosol and can act upon disordered, amorphous aggregates. Further, Hsp110, Hsp70,
and Hsp40 can enhance the activity of Hsp104 in the disaggregation of amyloid fibers
(Shorter, 2011).
All together, this evidence indicates that metazoan cells do possess
disaggregation activity. Elucidation of the mediating factors in protein refolding and
disaggregation would help in identifying new therapeutics for diseases caused by protein
misfolding. Indeed, it has been shown that Hsp104, despite being a yeast protein, can
be therapeutically efficacious in metazoan disorders such as Alzheimer’s and
Parkinson’s disease, albeit in generally in vitro settings (Vashist, Cushman, and Shorter,
2010), underscoring the potential of molecular chaperones in ameliorating disease. In
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chapter three, I examine the activity of Daxx in protein folding, potentially establishing it
as a novel molecular chaperone.
The Mammalian Cell Cycle
Cell cycle regulation is crucial to the survival of the cell not only because it
controls the growth of the cell, but also because it allows the cell time to detect and
repair genetic damage. The mammalian cell cycle consists of four distinct phases—G1
(gap phase), S (synthesis), G2 (gap phase), and M (mitosis) phases (Figure 1.7). Cells
that have temporarily or reversibly stopped dividing are said to enter a state of
quiescence known as G0. G1, S, and G2 are collectively known as interphase, where
the cell spends the majority of its time preparing for division via the acquisition of
nutrients and replication of its DNA (Vermeulen, Van Bockstaele, and Berneman, 2003).
The cell cycle is controlled by a number of checkpoints that facilitate the progression of
the cell through the cycle ensuring that the cell is free of any defects in DNA synthesis or
chromosome segregation (Malumbres, and Barbacid, 2009). The first checkpoint the cell
encounters is the restriction (R) point. Once they pass this point, cells are able to
proliferate without extracellular mitogenic stimuli (Pardee, 1974). The cell cycle is highly
influenced by the proper expression of cyclins and their associated cyclin-dependent
kinases (Cdks), which form specific complexes at each stage of the cell cycle to facilitate
proper progression (Figure 1.7).
During G0 and G1 phase, the cell cycle is influenced by external mitogenic
signals. Once activated by these extracellular signals, the D-type cyclins pair with their
catalytic partners, Cdk4 and Cdk6, to promote progression through G1 phase (Sherr,
and Roberts, 2004). The cyclin D-Cdk complexes work to promote cell division via the
inactivation of two classes of cell cycle inhibitors: negative regulators of S-phase gene
24

Figure 1.7. Schematic depicting the mammalian cell cycle.
The cell cycle is divided into four phases: G1 (first gap phase), S (DNA synthesis
phase), G2 (second gap phase), and M (mitosis). Cyclin-Cdk complexes regulate the
various stages of the cell cycle. G0 is a period of quiescence during which the cells have
temporarily or reversibly stopped dividing. The R denotes the restriction point at which
stage the cells do not require mitogenic signals to continue signaling.
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expression and the Cip/Kip family of proteins (Sherr, and Roberts, 2004). Cyclin D-Cdk
complexes are known to phosphorylate and functionally inactivate the retinoblastoma
protein (pRb) and the pRb-related proteins, p107 and p130 (Harbour, Luo, et al, 1999).
Inhibition of pRb leads to derepression of the E2F family of transcription factors, allowing
transcription of a variety of proteins necessary for DNA metabolism and replication,
ultimately allowing for progression into S phase. Additionally, the cyclin D-Cdk
complexes are able to sequester p27 (Kip1) and p21 (Cip1) away from cyclin E-Cdk2
and cyclin A-Cdk2, relieving Cdk2 inhibition by p27 and p21 (Sherr, and Roberts, 1995;
Toyoshima, and Hunter, 1994). If mitogenic signals are withdrawn, the cyclin D-Cdk
complexes dissociate, allowing for mobilization of p27 bound to those complexes. Once
freed from the complex, p27 is able to inhibit cyclin E-Cdk2 and promote exit from the
cell cycle (Poon, Toyoshima, and Hunter, 1995).
The activation of E2F by the cyclin D-Cdk complexes during G1 leads to the
transcription of cyclin E, allowing for the formation of cyclin E-Cdk2 complexes. This
complex also phosphorylates pRb, allowing for further activation of E2F activity (Ohtani,
DeGregori, and Nevins, 1995). pRb remains phosphorylated throughout the S, G2, and
M phases and becomes dephosphorylated during the transition from M to G1 by PP1
(Ludlow, Glendening, et al, 1993; Nelson, Krucher, and Ludlow, 1997). The cyclin ECdk2 complex is at maximal activity at the transition between G1 and S phase and its
activity significantly decreases at the beginning of S phase due to proteolytic
degradation of cyclin E (Clurman, Sheaff, et al, 1996). Cyclin E-Cdk2 is responsible for
the initiation of DNA synthesis and proper completion of S phase. As DNA replication
continues, cyclin E levels decrease and the level of the mitotic cyclins (cyclins A and B)
begins to increase (Sherr, and Roberts, 2004). Cyclin A-Cdk2 activity is first detected in
late G1 phase and steadily increases as the cells begin to replicate their DNA, after
26

which cyclin A is degraded before metaphase (Fung, and Poon, 2005). During S phase,
the cyclin A-Cdk2 complex can phosphorylate substrates that start DNA replication from
preassembled replication initiation complexes (Krude, Jackman, et al, 1997). After
proteolytic degradation of cyclin A, cyclin B-Cdk1 complexes begin the transition into M
phase (Mitra, and Enders, 2004). Activation of cyclin B-Cdk1 triggers its rapid
accumulation in the nucleus and its levels continue to rise until the beginning of mitosis,
after which they fall due to degradation of cyclin B. Activation of cyclin B-Cdk1 results in
the breakdown of the nuclear envelope and the initiation of prophase (Hagting, Jackman,
et al, 1999).
It is clear that the cell cycle is a carefully controlled process that utilizes cyclinCdk complexes for proper progression. However, this prevailing dogma has been
challenged suggesting that not all these cyclins and Cdks are required for proper cellular
proliferation. Genetic studies in mice have shown that mouse strains lacking each of the
D-cyclins separately are mostly viable and display very narrow and restricted
developmental abnormalities (Ciemerych, Kenney, et al, 2002; Fantl, Stamp, et al, 1995;
Sicinska, Aifantis, et al, 2003; Sicinski, Donaher, et al, 1995). Cyclin D1-deficient mice
are generally smaller in size and have severe hypoplastic retinas and pregnancyinsensitive mammary glands. Deletion of cyclin D2 in mice leads to female sterility due to
the inability of ovarian granulosa cells to proliferate normally in response to folliclestimulating hormone (FSH). Male mice are still fertile but display hypoplastic testes
(Sicinski, Donaher, et al, 1996). Finally, mice deficient in cyclin D3 have lymphoid
abnormalities but are still viable (Sicinska, Aifantis, et al, 2003). Mice lacking all three
cyclins appear normal until E13.5; however, they eventually die by E17.5 due to severe
anemia and cardiac abnormalities. Interestingly, fibroblasts derived from these embryos
were sustainable in culture albeit requiring higher mitogen concentrations to grow
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(Kozar, Ciemerych, et al, 2004).
The necessity of the Cdks has also been studied and knockout mice lacking the
various Cdks have been generated. Cdk1 -/- mice displayed arrested embryonic
development at the blastocyst stage and MEFs lacking Cdk1 were unable to proliferate
as the cells underwent premature senescence, suggesting that Cdk1 is essential for
proliferation (Diril, Ratnacaram, et al, 2012). Conversely, deletion of Cdk2 was shown to
have no effect on mitosis in mice, but was important for the completion of prophase I
during meiosis in both male and female germ cells (Berthet, Aleem, et al, 2003; Ortega,
Prieto, et al, 2003). Mice deficient in Cdk4 and Cdk6 have also been generated; they are
viable and show very narrow, tissue-specific defects (Kozar, and Sicinski, 2005). When
only Cdk4 is deleted, the mice have a reduced body size, are sterile, and become
diabetic due to a reduced number of pancreatic β cells (Martin, Hunt, et al, 2003; Rane,
Dubus, et al, 1999). Cdk6 -/- mice display defective hematopoiesis and lower cellularity
in the thymus and spleen. The loss of Cdk6 also leads to delayed G1 progression in
lymphocytes. Further observations suggest that Cdk6 is more essential for the
expansion of differentiated populations rather than for proliferation of hematopoietic
precursors (Malumbres, Sotillo, et al, 2004). The same study characterized double
knockout Cdk4;Cdk6 -/- mice and demonstrated that embryos died beginning at E14.5
until the end of gestation due to severe anemia and major defects in multiple
hematopoietic lineages. Many tissues still had normal proliferation rates and fibroblasts
cultured from the double knockout embryos were able to cycle relatively normally.
The importance of the cell cycle proteins is underscored by the fact that their
deregulation has been observed in various types of cancer. (Vermeulen, Van
Bockstaele, and Berneman, 2003). In fact, overexpression of the D and E cyclins and
Cdk4 are commonly observed in human tumors (Akli, and Keyomarsi, 2003; An,
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Beckmann, et al, 1999; Diehl, 2002; Donnellan, and Chetty, 1999; Yu, Sicinska, et al,
2006). It is possible that pharmacological disruption of these complexes may yield
therapeutic efficacy for specific cancers. Yet, ambiguity exists regarding the necessity of
these different proteins in cell cycle progression. Therefore, determining the cell-type
specificity and regulation of these canonical cell cycle proteins is essential for
understanding cellular proliferation. In chapter four, I discuss a novel function for Daxx
as a potential regulator of the cell cycle associated protein, Cdk6.
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CHAPTER 2: THE ROLE OF DAXX IN p53 REGULATION
INTRODUCTION
Tumor suppressors are necessary to prevent the proliferation of cells carrying
cancer-causing alterations. These alterations can include the activation of an oncogene
or DNA damage. The major responder to these cellular stresses is the tumor suppressor
p53. Upon activation, p53 can induce apoptosis, cell cycle arrest, or senescence,
amongst many other activities (Vogelstein, Lane, and Levine, 2000; Vousden, and
Prives, 2009). Due to its potent anti-proliferative activity, p53 is highly constrained by the
E3 ubiquitin ligase, Mdm2 (Haupt, Maya, et al, 1997; Kubbutat, Jones, and Vousden,
1997). In unstressed cells, p53 levels are maintained at a low level via ubiquitination by
Mdm2; however, upon the induction of various stresses, Mdm2 stabilization is impaired
and p53 levels are able to rise (Vogelstein, Lane, and Levine, 2000). Upon DNA
damage, ATM is activated, leading to phosphorylation of p53 at Ser15 and at Ser20 by
Chk2, a downstream kinase of ATM. These phosphorylation events cause stabilization
of p53, partially via disruption of the p53-Mdm2 complex (Banin, Moyal, et al, 1998;
Canman, Lim, et al, 1998; Shieh, Ahn, et al, 2000). Subsequent studies demonstrated
that mutation of the phosphorylation sites in murine p53 do not robustly reduce p53
stabilization after DNA damage, indicating that other events are necessary for sustained
p53 activation (Chao, Hergenhahn, et al, 2003; MacPherson, Kim, et al, 2004; Sluss,
Armata, et al, 2004).
Our lab has previously shown that Daxx is a critical regulator of Mdm2 via the
simultaneous association of Daxx with Hausp, a deubiquitinase, and Mdm2 in
unstressed cells (Tang, Qu, et al, 2006). Thus, Daxx bridges Hausp to Mdm2, which
deubiquitinates Mdm2 allowing for its stability and consequential p53 inactivation.
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Induction of DNA damage leads to disruption of the Daxx-Mdm2-Hausp complex in an
ATM-dependent manner allowing for p53 activation (Tang, Qu, et al, 2006). It is known
that ATM phosphorylates Ser395 on Mdm2 and that this event interferes with the
inhibitory effect of Mdm2 on p53 (Maya, Balass, et al, 2001). More recently it has been
shown that ATM phosphorylates multiple sites in the C-terminus of Mdm2 upon DNA
damage. These sites act redundantly to inhibit p53 degradation and stabilize p53
(Cheng, Chen, et al, 2009). When a phospho-mimic mutant of Mdm2 (S395D) was used
to test its ability to associate with Daxx, it exhibited similar binding to Daxx as compared
to wild-type Mdm2. This suggests that the Daxx-Mdm2-Hausp complex is potentially
being regulated by additional phosphorylation events mediated by ATM. In the present
study, we hypothesize that Daxx is an ATM target and that Daxx phosphorylation is
important for its interaction with Mdm2 and consequential p53 activation. This study was
recently published and demonstrated that Daxx is phosphorylated at Ser564 in response
to DNA damage in an ATM-dependent manner (Tang, Agrawal, et al, 2013). Dr. Jun
Tang identified the phosphorylation site on Daxx and raised the phospho-specific
antibody to the aforementioned site. She also determined the ATM-dependence of this
site in vivo. I performed the in vitro kinase assay demonstrating that ATM directly
phosphorylates Daxx. I also executed subsequent analyses of Daxx phosphorylation
regarding Mdm2 stability and p53 activation.
RESULTS
Daxx is phosphorylated at Ser564 by ATM in response to DNA damage
To determine if ATM phosphorylates Daxx during DNA damage, an antibody that
recognizes the ATM substrate consensus sequence X-Ser/Thr-Gln (where X is a
hydrophobic residue) was used to detect Daxx phosphorylation in human lung
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carcinoma (H1299) cells. The cells were transfected with Flag-Daxx and then treated
with the genotoxic drug etoposide (ETP). Western analysis indicated that Daxx is
phosphorylated soon after DNA damage induction and that this phosphorylation persists
for at least eight hours (Figure 2.1). To map the phosphorylation site, residues from the
N-terminus of Daxx were progressively deleted and these Daxx truncation mutants were
transfected into H1299 cells treated with or without etoposide (Figure 2.2, A and B).
Daxx phosphorylation was not detected for amino acids 570-740 but was detected in the
other fragments, suggesting that the phosphorylation site resides within residues 340570 of Daxx (Figure 2.2B). Analysis of this region revealed two potential ATM consensus
sites: MAS424QG and PVS564QL. Both Ser424 and Ser564 were mutated to S424A and
S564A and expressed in H1299 cells treated with or without etoposide. The S564A
mutation, but not the S424A mutation, abolished Daxx phosphorylation upon treatment
with etoposide indicating that S564 is the major ATM-targeted phosphorylation site on
Daxx upon DNA damage (Figure 2.2C, lane 4 vs. 2 and 6). The Daxx Ser564 ATM
consensus site is evolutionarily conserved across mammalian species, but not in fish or
flies (Figure 2.3).
Phosphorylation of endogenous Daxx upon DNA damage
An antibody specific for the phosphorylated Ser564 residue on Daxx was made
to confirm the modification of this site upon DNA damage (pS564-Daxx). This antibody
detected phosphorylation of Daxx upon DNA damage in human osteosarcoma (U2OS)
cells (Figure 2.4A, lane 2) and this signal was diminished when Daxx was knocked down
using siRNA (Figure 2.4A, lane 4 vs. 2), underscoring the specificity of this antibody
toward Daxx. To confirm that this antibody was recognizing phosphorylated Ser564,
either wild-type, S564A, or S424A Daxx was expressed in H1299 cells and challenged
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Figure 2.1. Daxx is phosphorylated upon DNA damage.
p53-deficient H1299 cells were transiently transfected with Flag-Daxx. 24 h later, the
cells were treated with 10 µM etoposide (ETP) for the indicated durations. Cells were
lysed and Flag-Daxx was immunoprecipitated with anti-Flag mAb beads and analyzed
by western blot with antibodies against Daxx or phosphorylated ATM substrate
consensus site (pS/T-Q). Performed by Dr. Jun Tang.
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Figure 2.2. Daxx is phosphorylated at Ser564 upon DNA damage.
(A) Schematic representation of full length Daxx and its N-terminal deletion mutants.
PAH, paired amphipathic helical domains. D/E, acid-rich region. SPT, Ser/Pro/Thr-rich
domain. The amino acids in full length Daxx and in the N-terminus of each deletion
mutant, and phosphorylation status (Pi) of these mutants are indicated. (B) H1299 cells
expressing full-length (FL) Daxx and each of the deletion mutants were treated with 10
µM ETP for 1 h. Phosphorylation of these proteins was analyzed using Daxx and ATM
substrate consensus site (pS/T-Q) antibodies. Exogenous Daxx phosphorylation existing
before DNA damage was observed in some experiments, but not others. (C)
Phosphorylation of Daxx, Daxx S424A, and Daxx S564A upon DNA damage was
analyzed as in (B). Performed by Dr. Jun Tang.
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Figure 2.3. Ser564 of Daxx is evolutionarily conserved.
Alignment of the human Daxx (gi|48146287) sequence around Ser564 with the
corresponding Daxx sequences from Bos taurus (gi|296474559), Canis lupis familiaris
(gi|55956960), Mus musculus (gi|2253707), Rattus norvegicus (gi|18148939), Salmo
salar (gi|148362139), and Drosophila melanogaster (gi|54144924). Alignment was run
using Clustal W2 (Goujon, McWilliam, et al, 2010; Larkin, Blackshields, et al, 2007).
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Figure 2.4. Phosphorylation of endogenous Daxx upon DNA damage.
(A) U2OS cells were transfected with control or Daxx siRNA and treated with 10 µM ETP
for 1 h. Cell lysates were analyzed by western blot using the phospho-specific Daxx
antibody, pS564-Daxx. (B) Western blot analysis of H1299 cells transfected with wildtype (WT) Daxx, Daxx S564A, or Daxx S424A and treated with ETP for 1 h using pS564Daxx. (C) Phosphorylation of endogenous Daxx in multiple cell lines treated with and
without etoposide for 1 h. Cell lysates were analyzed using antibodies against pS564Daxx, Daxx, p53, and actin. Saos-2 (human osteosarcoma, p53 null); HT1080 (human
fibrosarcoma); HeLa (human cervix adenocarcinoma, p53 null); 293T (human embryonic
kidney); IMR90 (primary human lung fibroblast). Performed by Dr. Jun Tang.
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with etoposide. The phosphorylated Daxx band intensity was greatly decreased when
Daxx S564A was expressed compared to wild-type or S424A Daxx (Figure 2.4B, lane 4
vs. lanes 2 and 6), further confirming the specificity of this antibody for phosphorylated
Ser564. When this antibody was applied to cell lysates from a variety of cancer and
primary cell lines, it was able to recognize DNA damage-induced Daxx phosphorylation
in all cases, indicating the generality of this effect and its independence of p53 status
(Figure 2.4C).
Daxx is phosphorylated by ATM in vivo and in vitro
To confirm the ATM-dependence of this phosphorylation event, in vivo and in
vitro experiments were performed. First, H1299 cells were treated with ATM siRNA and
etoposide. The lysates were analyzed with the phospho-specific antibody against
Ser564 of Daxx, which showed that endogenous Daxx phosphorylation was diminished
in ATM-depleted cells (Figure 2.5A, lane 4 vs. 2). To determine whether ATM directly
phosphorylates Daxx at Ser564, we performed an in vitro kinase assay with various
purified recombinant ATM and Daxx proteins in the presence of γ-32P-ATP. Daxx was
then analyzed by autoradiography, as well as by western blot using the anti-pS564-Daxx
antibody. Daxx was phosphorylated in vitro by wild-type ATM, but not by a kinase-dead
(KD) ATM mutant (Figure 2.5B, lanes 1 vs. 2). The small amount of pS564-Daxx signal
in the reaction containing ATM KD (lane 2) was likely due to phosphorylation that preexisted on the Daxx protein purified from HEK293 cells, because minimal
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P

incorporation of Daxx was detected in this reaction. Compared to Daxx, ATM-mediated
phosphorylation of Daxx S564A was weakly detected by
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P incorporation (lane 3), but

not by anti-pS564 antibody (lane 4). This weak phosphorylation likely occurred on an
amino acid residue(s) distinct from S564. Together, these data indicate that ATM can
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Figure 2.5. Daxx is phosphorylated by ATM in vivo and in vitro.
(A) H1299 cells treated with ATM siRNA or control siRNA were subject to DNA damage
and analyzed for phosphorylation using pS564-Daxx antibody. Performed by Dr. Jun
Tang. (B) In vitro kinase assay depicting Ser564 phosphorylation by ATM. Top two
panels: phosphorylated Daxx was detected by autoradiography (32P-Daxx) and western
blot (pS564-Daxx). Bottom two panels: input of ATM and Daxx proteins were analyzed
by western blot and Coomassie staining, respectively.
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phosphorylate Daxx directly and mainly at Ser564.
Phosphorylation of Daxx at Ser564 regulates its interaction with Mdm2
Next, we sought to determine if phosphorylation of Daxx by ATM affected its
interaction with Mdm2 and if this would have downstream consequences on the
activation of p53. To determine if the binding of Daxx and Mdm2 was affected, we
performed an immunoprecipitation where HA-Daxx or HA-Daxx S564A was cotransfected with Flag-Mdm2 in H1299 cells and Mdm2 was pulled down using anti-Flag
beads. The co-immunoprecipitation assay showed that wild-type Daxx and Mdm2 readily
dissociated from each other upon etoposide treatment; however, Daxx S564A continued
to associate with Mdm2 during etoposide treatment, suggesting that the lack of Ser564
phosphorylation on Daxx enhances its interaction with Mdm2 (Figure 2.6A, lanes 6-8 vs.
3-5).
It is known that ATM can phosphorylate Mdm2 at Ser395 upon DNA damage
(Maya, Balass, et al, 2001). We evaluated how the binding of wild-type and S564A Daxx
would be affected with a phospho-mimic mutant of Mdm2 (S395D). Compared to wildtype Daxx, Daxx S564A was able to bind more strongly to Mdm2 S395D suggesting that
a lack of phosphorylation at Ser564 on Daxx increases its ability to bind to
phosphorylated Mdm2 (Figure 2.6B, lanes 3 vs. 2). Furthermore, a previous study
reported that Daxx could be phosphorylated at Ser712 by the ATM/ATR signaling
network (Matsuoka, Ballif, et al, 2007). To examine whether this phosphorylation site
was involved in the Mdm2 interaction, a mutant form of Daxx was created (S712A) along
with a double mutant where both the Ser564 and Ser712 were mutated to alanine (2SA).
Daxx S712A displayed a similar binding affinity for Mdm2 S395D as wild-type Daxx
(Figure 2.6B, lanes 4 vs. 2). Additionally, Daxx 2SA and Daxx S564A had
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Figure 2.6. Phosphorylation of Daxx at Ser564 regulates its interaction with Mdm2.
(A) H1299 cells were transfected with either HA-Daxx or HA-Daxx S564A alone, or
together with Flag-Mdm2. Cells were treated with MG132 (20 µM) for 4 h and ETP (20
µM) for the indicated times. Cell lysates were incubated with anti-Flag mAb beads. Input
and immunoprecipitated proteins were analyzed by western blot using HA-HRP antibody
for Daxx and Flag-HRP antibody for Mdm2. (B) HA-Mdm2 S395D was transfected alone
and together with the indicated Flag-Daxx plasmids into p53-/- Mdm2-/- MEFs (mouse
embryonic fibroblasts). Cell lysates were incubated with anti-Flag mAb beads. The input
lysates and immunoprecipitated proteins were analyzed by western blotting.
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indistinguishable interactions with Mdm2 S395D (Figure 2.6B, lanes 5 vs. 3). These
results indicate that phosphorylation at Ser564 is the main event that disrupts the
interaction of Daxx with phosphorylated Mdm2.
To determine if Daxx phosphorylation mediated the stability of Mdm2, we
performed half-life analyses using the protein translation inhibitor cycloheximide. First,
we expressed Mdm2 alone or with wild-type or Daxx S564A in H1299 cells. Wild-type
Daxx was able to increase the protein expression and half-life of Mdm2 compared to
when Mdm2 was expressed alone (Figure 2.7A, lanes 5-8 vs. 1-4) and Daxx S564A
further enhanced the stability and half-life of Mdm2 (Figure 2.7A, lanes 9-12 vs. 5-8). To
determine the effect of Daxx S564A on endogenous Mdm2, U2OS stable cell lines were
established via retroviral transduction to express wild-type Daxx or Daxx S564A. The
cells lines stably expressing Daxx S564A showed a greater ability to stabilize Mdm2 and
increase its half-life, when compared to wild-type Daxx (Figure 2.7B, lanes 9-12 vs. 5-8).
Finally, we tested whether this increase in half-life also occurred upon DNA damage. We
expressed Mdm2 together with either Daxx or Daxx S564A. Etoposide was used to
induce DNA damage after which cycloheximide was administered to the cells. Mdm2
stability was enhanced in the presence of Daxx, as expected (Figure 2.7C, lanes 5-8 vs.
1-4). Mdm2 stability was further enhanced when Daxx S564A was co-expressed, even
though Daxx S564A expressed at a much lower level than wild-type Daxx (Figure 2.7C,
lanes 9-12 vs. 5-8).
Our previous study indicated that Daxx is able to stabilize Mdm2 via association
with Hausp (Tang, Qu, et al, 2006). To confirm that Daxx S564A-mediated stabilization
of Mdm2 was also dependent upon Hausp, we treated U2OS cells with either Hausp or
control siRNA and expressed increasing amounts of Daxx S564A. Endogenous Mdm2
stability is enhanced in the presence of Daxx S564A (Figure 2.8, lanes 2-4 vs. 1), but the
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Figure 2.7. Phosphorylation of Daxx at Ser564 regulates the half-life of Mdm2.
(A) H1299 cells were transfected with HA-Mdm2 alone or with Flag-Daxx or Flag-Daxx
S564A. Cells were treated with CHX (50 µg/ml) for indicated time and subjected to
western blot analysis. Tubulin and GFP are shown as controls for sample loading and
transfection efficiency, respectively. (B) Daxx S564A can prolong the half-life of
endogenous Mdm2. U2OS cells stably expressing Flag-Daxx or Flag-Daxx S564A were
treated with CHX (20 µg/mL) for the indicated times. Samples were analyzed using
Mdm2, Daxx, and tubulin antibodies. (C) Daxx S564A can prolong the half-life of Mdm2
upon DNA damage. Flag-Mdm2 was transfected alone or together with the indicated HADaxx plasmids into p53-/- Mdm2-/- MEFs. Cells were treated with ETP (20 µM) for 1 h
prior to cycloheximide (CHX, 50 µg/ml) treatment for indicated times. GFP and actin are
shown as controls for transfection efficiency and sample loading, respectively. Asterisk
indicates non-specific band.
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Figure 2.8. The effect of Daxx S564A on Mdm2 is dependent upon Hausp.
Increasing amounts of Flag-Daxx S564A were transfected into U2OS cells treated with
either control or Hausp siRNA and analyzed by western blot. Actin and GFP are shown
as controls for sample loading and transfection efficiency, respectively.
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effect is greatly diminished in Hausp-silenced cells (Figure 2.8, lanes 5-8 vs. 1-4).
ATM-mediated phosphorylation of Daxx leads to p53 activation
We next examined if Daxx phosphorylation had consequences for p53 activation.
Using human breast adenocarcinoma (MCF-7) cells, we stably expressed wild-type or
S564A Daxx and assessed p53 levels. When Daxx S564A was present, there was an
impairment of p53 activation upon etoposide treatment, presumably via greater
stabilization of Mdm2 as compared to wild-type Daxx (Figure 2.9). The functional
consequence of lower p53 levels was analyzed by measuring the protein (Figure 2.9A)
and mRNA levels (Figure 2.9B) of the major p53 transcriptional target, p21. In both
instances, p21 induction was weakened in the presence of Daxx S564A. These results
indicate that ATM-mediated phosphorylation of Daxx upon DNA damage leads to Mdm2
instability and p53 activation.

44

Figure 2.9. ATM-mediated phosphorylation of Daxx at Ser564 leads to p53
activation.
MCF-7 (A, done by Dr. Jun Tang) and U2OS (B) cells stably expressing Flag-Daxx or
Flag-Daxx S564A were treated with 10 µM ETP for 8 h. Protein (A) and mRNA (B)
expression was analyzed by western blot and quantitative RT-PCR.
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MATERIALS AND METHODS
Antibodies and plasmids - Antibodies for the following proteins/epitopes were purchased
from the indicated sources: actin (A2066), tubulin (T4026), and Flag (mouse monoclonal,
M2, free (F3615) and conjugated to beads (A2220), and rabbit polyclonal (F7425))
(Sigma); ATM (Ab-3) and Mdm2 (Ab-1 and Ab-3) (Calbiochem); Daxx (M-112), p53 (DO1), (Santa Cruz Biotechnology); phosphorylated ATM/ATR consensus site (X-pSer/ThrGln, where X is a hydrophobic residue) (#2851, Cell Signaling); GFP (JL-8, Clontech);
Hausp/USP7 (A300, Bethyl Laboratories, Inc.); HA conjugated to horseradish
peroxidase (Roche). Antibody specific to Phospho-Daxx Ser564 was made by Invitrogen
using peptide PEELTLEEESPVpSQLFELEIEA. Plasmids encoding HA- or Flag-tagged
Mdm2 and Daxx for transient transfection were made in pRK5, and plasmids encoding
Flag-tagged Daxx for stable infection were made in the retroviral vector pBabe-puro.
They were either previously described (Tang, Qu, et al, 2006), or generated for this
study by PCR and confirmed by sequencing. ATM and ATM KD expression plasmids
were kindly provided by Dr. M. B. Kastan.

Cell Culture - All cells were obtained from the ATCC. H1299 cells were grown in RPMI40 media and all other cell lines in Dulbecco’s modified Eagle’s medium, supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin. For generating Daxx and
control stable cell lines, retroviral constructs for Flag-Daxx and Flag-Daxx S564A, as
well as the parental vector pBabe-puro, were separately transfected into either phoenix
cells along with the retroviral packaging vector pCL-Ampho, or HEK293T cells along with
pcgp (which encodes gag pol) and pHIT 456 (which encodes retroviral envelope). 48-72
h after transfection, the retrovirus-containing medium was used to infect U2OS or MCF-7
cells in the presence of 8 µg/mL polybrene. The infected cells were selected in the
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presence of 2 µg/ml puromycin for 4-5 days.

Immunoprecipitation and western blot - Transfections were carried out using
Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen) according to the
manufacturer’s instructions. siRNA sequence for Daxx was: CAG AAA CAT TAA TAA
ACA ATA (Qiagen). siRNA sequence for Hausp was CCC AAA TTA TTC CGC CGG
CAA A (Qiagen). 24 h after transfection, cells were lysed in IP lysis buffer (20 mM TrisHCl at pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-40, 100 mM NaF, 1 mM
PMSF, 1 mM DTT, 1X complete protease cocktail (Roche), and 10% glycerol). Samples
were fractionated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Flag-Daxx or Flag-Mdm2 was immunoprecipitated with anti-Flag mAb
beads and analyzed by western blot with anti-Daxx antibody (1:5,000), antiphosphorylated ATM/ATR consensus site (pS/T-Q) antibody (1:500), anti-Flag antibody
(mouse or rabbit, 1:5,000), or anti-HA antibody (1:5,000).

Kinase Assay - Flag-tagged ATM wild-type (WT), ATM kinase dead (KD), Daxx, and
Daxx S564A were separately expressed in 293T cells and purified using M2 beads as
previously described (Cheng, Chen, et al, 2009; Tang, Wu, et al, 2004). Daxx or Daxx
S564A was incubated with ATM or ATM KD at 30°C for 1 h in kinase buffer (50 mM
HEPES at pH 7.5, 150 mM NaCl, 20 mM MnCl2, and 1% Triton X-100) containing 2 µM
ATP and 10 µCi γ-32P-ATP. Samples were fractionated on a 7.5% SDS-PAGE gel and
detected by autoradiography and western blot.

Quantitative RT-PCR analysis - Total RNA was isolated from cells using TRIzol
(Invitrogen). Reverse Transcription was performed using the First Strand cDNA
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Synthesis Kit (Marligen Biosciences). A Taqman Gene Expression Assay (Applied
Biosystems) with validated human p21 (Hs00355782_m1) and 18s rRNA (4333760F)
primers/probe sets (Applied Biosystems) were used for qPCR and analyzed.
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CHAPTER 3: DAXX AS A NOVEL MOLECULAR CHAPERONE

INTRODUCTION
Protein aggregation in cells arises due to the accumulation of misfolded proteins
and leads to proteinopathies that can cause neurodegenerative diseases, diabetes, and
cancer (Aguzzi, and O'Connor, 2010; Dobson, 2006; Xu, Reumers, et al, 2011). To
contend with errors in protein folding, the cell maintains a sophisticated protein
homeostasis network consisting of molecular chaperones to prevent aggregation or
promote degradation of misfolded proteins (Dobson, 2003). Proteostasis is achieved
using an extensive network of proteins, predominantly mediated via molecular
chaperones (Hartl, Bracher, and Hayer-Hartl, 2011; Kim, Hipp, et al, 2013).
The Hsp70 class of molecular chaperones assists a wide range of folding
processes including prevention of aggregation, promotion of folding to the native state,
and solubilization of aggregated proteins (Mayer, and Bukau, 2005). Hsp70s work with
the Hsp40 family of molecular chaperones to prevent aggregation through binding with
hydrophobic patches on their substrate molecules, preventing inappropriate
intermolecular associations, which could lead to aggregation (Mayer, and Bukau, 2005).
Hsp70 chaperones can also promote the refolding of non-native proteins, yet the
mechanism as to how this occurs is unclear. It is thought that via repetitive binding and
release cycles of the substrate with Hsp70, the free concentration of the substrate is
kept low to prevent aggregation and free molecules are allowed to fold to the native state
(Mayer, and Bukau, 2005). Alternatively, Hsp70 may promote local unfolding of the
protein through binding and release cycles, after which the protein can spontaneously
fold into the native structure (Ben-Zvi, and Goloubinoff, 2001; Bukau, and Horwich,
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1998; Slepenkov, and Witt, 2002). Hsp70 chaperones can also promote the
solubilization of misfolded and aggregated proteins; however, this only occurs via
association of Hsp70 with Hsp104, a member of the Hsp100 class of chaperones.
Intriguingly, there is no metazoan homolog for Hsp104 and to date, identification
of a mammalian protein capable of renaturing large protein aggregates has remained
elusive. Hsp104, a homolog of the AAA+ ATPase family, exists in the vast majority of
bacteria and eukaryotes, but not in metazoan species (Doyle, and Wickner, 2009;
Shorter, 2008; Vashist, Cushman, and Shorter, 2010). Hsp104 is able to rescue
chemically denatured proteins after they have formed higher molecular weight
aggregates, in combination with Hsp70 and Hsp40 (Glover, and Lindquist, 1998). It is
unclear if animal cells possess protein disaggregases, but a potent mammalian
disaggregating system has been discovered using a cell-free system, whereby Hsp110,
a divergent relative of Hsp70, synergizes with Hsp70 and Hsp40 to confer protein
disaggregase activity to the mammalian cytosol (Shorter, 2011).
Despite these discoveries, it is still unclear how Hsp70 promotes the refolding of
non-native structures and how metazoan cells counteract large protein aggregates. We
propose that Daxx may be a mediator of protein folding in mammalian cells for several
reasons. First, Daxx has a diverse array of binding partners leading it to have seemingly
disparate functions within in the cell (Salomoni, and Khelifi, 2006). This is similar to the
Hsp70 proteins, in that they demonstrate broad substrate specificity shown through their
ability to associate with the entire spectrum of heat-denatured proteins in E. coli (Mogk,
Tomoyasu, et al, 1999). Second, Daxx contains an acid-rich region enriched in Glu and
Asp acid residues between amino acids 414 and 505, constituting a polyanionic region.
This region is reminiscent of the C-terminal portion of the smaller heat shock proteins,
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without which their activity is diminished (Narberhaus, 2002). Additionally, polyanions
such as nucleic acids and tubulin demonstrate in vitro chaperone activity (Guha, Manna,
et al, 1998; Jones, Yazzie, and Middaugh, 2004; Rentzeperis, Jonsson, and Sauer,
1999). Further, the nucleoplasmin (NPM) family of proteins encompasses a group of
nuclear chaperones that contain a conserved N-terminus within which lies a short acidic
tract—a domain responsible for their oligomerization and chaperone function (Frehlick,
Eirin-Lopez, and Ausio, 2007). These activities are most likely mediated by electrostatic
interactions between the polyanions and client proteins. Finally, Daxx is a histone
chaperone for the histone variant H3.3 that works with ATRX to assemble H3.3containing nucleosomes (Drane, Ouararhni, et al, 2010; Elsaesser, and Allis, 2010;
Elsasser, Huang, et al, 2012; Lewis, Elsaesser, et al, 2010). Its interaction with H3.3 has
been mapped to a region within the central portion of Daxx, partially encompassing the
acid-rich region (Drane, Ouararhni, et al, 2010). It is possible that its histone chaperone
activity extends beyond deposition of H3.3 into chromatin; Daxx may also be able to
assist H3.3 to attain its native structure. Additionally, it has been shown that Daxx
depletion leads to accumulation of a soluble pool of newly synthesized H3.3 in the
nucleoplasm, preventing H3.3 from localizing to PML-NBs (Delbarre, Ivanauskiene, et al,
2013). In their case, solubility refers to free H3.3 in nucleoplasm or cytoplasm. The idea
that Daxx can associate with newly synthesized proteins is reminiscent of the cotranslational folding activity of some of the molecular chaperones.
In the current study, we hypothesize that Daxx is a novel molecular chaperone.
We found that Daxx has refolding activity toward denatured luciferase and wild-type p53.
Daxx can also increase the solubility and activity of luciferase upon heat shock both in
vitro and in vivo. Deletion mutant analysis reveals that not only is the acid-rich region of
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Daxx important for its protein folding activity, but also a paired amphipathic helical
domain near its N-terminus. These results indicate that Daxx is a candidate as a novel
molecular chaperone that has the ability to refold misfolded protein species. This activity
may also underlie the diverse set of proposed functions for Daxx.
RESULTS
Daxx can increase protein levels of luciferase in a transcription- and Hauspindependent manner

A commonly used substrate for the assaying of protein folding is luciferase.
Luciferase is highly thermolabile and its activity can be easily monitored using
luminescence. To examine the possibility that Daxx has an effect on luciferase
expression in vivo, we expressed Flag-NLS-luciferase (where NLS is a nuclear
localization sequence), Flag-Daxx, and GFP-Hsp70 in U2OS cells, as indicated (Figure
3.1A). Upon Daxx overexpression, luciferase protein levels increased in a dosedependent manner; however, luciferase levels were unchanged upon Hsp70
overexpression, as seen previously (Kampinga, Kanon, et al, 2003) (Figure 3.1A, lane 6
vs. lanes 3-5). To exclude the possibility that Daxx was affecting the transcription of
luciferase, Flag-Daxx was expressed with Flag-NLS-luciferase for both qPCR (Figure
3.1B) and western analysis (Figure 3.1C). Daxx overexpression had little effect on
luciferase gene expression, but did increase luciferase protein levels (Figure 3.1C, lanes
2 and 3).
Daxx is known to form a complex with Hausp, which leads to stabilization of
Mdm2 via the deubiquitinase activity of Hausp (Tang, Qu, et al, 2006). To examine if the
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Figure 3.1. Daxx can increase protein levels of luciferase in a transcriptionindependent manner.
(A) U2OS cells were transfected with Flag-NLS-luciferase and increasing amounts of
Flag-Daxx or GFP-Hsp70, as indicated. Cell lysates were analyzed by western blot. (B,
C) The increase of luciferase expression is not dependent upon Daxx-mediated
transcription. U2OS cells were transfected with Flag-NLS-luciferase and increasing
amounts of Flag-Daxx concurrently for mRNA analysis via qPCR (B) and for protein
analysis via western (C).
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Daxx-Hausp interaction had a role in luciferase stabilization, we treated H1299 cells with
Hausp or control siRNA and expressed increasing amounts of Daxx. The ability of Daxx
to increase luciferase protein levels was unaffected by Hausp knockdown (Figure 3.2,
lanes 5-6 vs. 2-3). These results show that Daxx can increase luciferase protein levels in
vivo in a transcription- and Hausp-independent manner.
Daxx can renature heat-denatured luciferase in vitro
The observation that Daxx could increase luciferase protein levels in cells led us
to posit that Daxx may have chaperone-like effects in vitro. To test this, we constructed a
double-tagged Daxx with a glutathione-S-transferase (GST) tag at the N-terminus and a
poly-histidine (6xHis) tag at the C-terminus. This Daxx fusion protein was purified from
bacteria using a tandem-affinity approach followed by ion-exchange chromatography
(Figure 3.3, A and B). To confirm the purity of Daxx, all bands that were visible by
Coomassie staining were sent for mass spectrometry analysis (Figure 3.3B, lane 2). All
bands were identified as Daxx, underscoring the purity of our purified Daxx. Upon
confirmation that Daxx was pure, we performed traditional chaperone assays.
One characteristic of conventional chaperones, including those of the Hsp70/40
family, is their ability to prevent the denaturation of substrates. To perform this
experiment, luciferase was concurrently incubated at 42ºC with GST and lysozyme as
negative controls, Daxx (denoted as Daxx-His hereafter), and Hsp70/40 with ATP as a
positive control. Daxx was unable to prevent loss luciferase of activity; however, the
combination of Hsp70/40 was able to prevent denaturation of luciferase, as expected
(Kubo, Tsunehiro, et al, 1999) (Figure 3.4A). For the same experiment when the
Hsp70/40 data was removed from analysis, we were able to better see the kinetics of
luciferase activity upon incubation with the other proteins. Strikingly, it seemed that Daxx
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Figure 3.2. Daxx can increase protein levels of luciferase in a Hausp-independent
manner.
Increasing amounts of Flag-Daxx were transfected with Flag-NLS-luciferase into H1299
cells. The cells were then treated with control or Hausp siRNA and analyzed by western
blot. Actin and GFP are shown as controls for loading and transfection efficiency,
respectively.
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Figure 3.3. Protocol for Daxx purification.
(A) Schematic illustrating purification scheme when GST cleavage was required. When it
was not required, that step was switched with protein elution using GSH. (B) Coomassiestained gel depicting purity of Daxx-His before and after ion-exchange (IEX)
chromatography.
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Figure 3.4. Daxx cannot prevent denaturation of luciferase in vitro.
(A) Heat-denatured luciferase (5 nM) was incubated with LRB or 50 nM GST, lysozyme,
Daxx, or Hsp70/40 supplemented with 10 mM ATP at 42ºC. Luciferase activity readings
were taken at the indicated times normalized to an undenatured control and represent
the means + SEM (n = 3). (B) Graph represents same data as in (A) except without
Hsp70/40 and zero time point data.
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was accelerating the denaturation of luciferase (Figure 3.4B), as luciferase had virtually
zero activity by five minutes, whereas the other conditions retained approximately 10%
of initial luciferase activity by five minutes. This result indicates that Daxx cannot prevent
the denaturation of luciferase; rather, it accelerates luciferase denaturation.
Another characteristic of chaperones is that they are able to promote the
refolding of denatured proteins. To assess this, luciferase was first denatured at 42ºC
and then distributed to reactions containing buffer, lysozyme as a negative control, Daxx,
or Hsp104/70/40 with ATP as a positive control. We used the Hsp104/70/40 system as a
positive control as this has previously been shown to be effective in the renaturation of
denatured substrates, such as luciferase and β-galactosidase (Glover, and Lindquist,
1998). Daxx was able to efficiently renature heat-denatured luciferase in vitro at 15(Daxx-His +) and 25-fold (Daxx-His ++) excess of the luciferase concentration, albeit to a
lesser extent than Hsp104/70/40 (Figure 3.5A). To further analyze the effect of Daxx on
luciferase, a sedimentation assay was performed where denatured luciferase was
incubated with buffer, lysozyme, or Daxx. The reactions were then centrifuged and
separated into supernatant, containing soluble luciferase, and pellet, containing insoluble
luciferase, fractions. The results indicate that Daxx was able to solubilize heat-denatured
luciferase aggregates, as more luciferase was visible in the soluble fraction when Daxx
was present (Figure 3.5B). Although with lysozyme it appeared that there was no
luciferase in the pellet, lysozyme was not solubilizing luciferase, as it was not visible in
the soluble fraction. This implies that the insoluble luciferase was part of an SDSinsoluble fraction that cannot be resolved using SDS-PAGE. Together, these results
suggest that Daxx is not able to prevent the denaturation of luciferase, but it is able to
promote the renaturation of an already denatured substrate.
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Figure 3.5. Daxx can renature heat-denatured luciferase in vitro.
(A) Heat-denatured luciferase (5 nM) was incubated with lysozyme (125 nM), Daxx (75
nM or 125 nM), and Hsp104/70/40 (125 nM) supplemented with 10 mM ATP at 25°C.
Luciferase activity was read at the indicated times and expressed as fold change over
undenatured control. Values represent means + SEM (n = 3). (B) Heat-denatured
luciferase (5 nM) was incubated with lysozyme (120 nM) and Daxx (30-120 nM) for 3 h
at 25°C and then partitioned into soluble and insoluble fractions via sedimentation at
17,000 x g for 15 min. Fractions were analyzed via western blot.
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To examine if Daxx had activity towards luciferase in vivo, we expressed FlagDaxx, Flag-NLS-luciferase, and GFP-Hsp70 in H1299 cells and performed an in vivo
luciferase assay (Michels, Kanon, et al, 1997) (Figure 3.6, A and B). In this assay, the
cells were first treated with cycloheximide to prevent the translation of endogenous
chaperone proteins upon heat shock. The cells were then heat shocked and allowed to
recover at 37ºC. Although Daxx did not protect luciferase during heat shock, and in fact
accelerated its loss of activity, it was able to recover it to a greater proportion (when
compared to heat shock activity) than luciferase alone or when luciferase was expressed
with Hsp70 (Figure 3.6A). The inability of Hsp70 to strongly recover luciferase activity
was not unexpected. It has been shown that Hsp70 is not as effective in renaturation of
luciferase in the nucleus as compared to the cytoplasm (Nollen, Brunsting, et al, 1999).
Additionally, Daxx was also able to increase the protein levels of luciferase under
control, heat shock, and recovery conditions (Figure 3.6B), confirming our earlier results
(Figure 3.1A). This evidence suggests that Daxx cannot prevent the denaturation of
luciferase; rather, it accelerates denaturation. It is then able to refold the denatured
luciferase in vivo to a greater proportion than heat shock proteins.
Daxx can refold misfolded luciferase, but not higher molecular weight aggregates
On the basis that Daxx could renature heat-denatured luciferase, we sought to
determine the physical properties of our luciferase substrate. To determine this, we used
size fractionation to visualize the distribution of differentially formed aggregates via urea
or heat denaturation. After denaturation, luciferase was applied to a gel filtration column
for size fractionation. Fractions were collected and assessed for distribution using
western blotting. When luciferase was denatured using heat denaturation, most of the
luciferase eluted at later fractions, indicative of oligomeric, dimeric, and monomeric
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Figure 3.6. Daxx accelerates denaturation of luciferase and enhances recovery of
luciferase in vivo.
(A, B) H1299 cells were transfected with luciferase and concurrently with either empty
vector, Flag-Daxx, or GFP-Hsp70. Cells were then treated with CHX for 30 min to
prevent translation of new chaperone proteins. Control samples were kept at 37°C for
duration of assay while heat shock and recovery samples were placed at 45°C for 30
min, after which the recovery samples were placed back at 37°C for 3 h. (A) Luciferase
activity is displayed relative to control samples. Values represent means + SEM (n = 4,
triplicate sampling). (B) Western analysis shows representative samples from each
condition and experiment.
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Figure 3.7. Daxx can renature heat-denatured luciferase.
(A, B) Heat-denatured luciferase (1 µM) was fractionated via gel filtration at 4ºC. The
elution profile was determined via western blotting (B). For refolding, column fractions in
the range of 2000 kDa-44 kDa were incubated with LRB, or 100 nM lysozyme, Daxx, or
Hsp104/70/40 supplemented with 10 mM ATP for 90 min at 25°C at which point
luciferase activity was determined (A).
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states (Figure 3.7, A and B). Selected elution fractions were then incubated with buffer,
lysozyme, Daxx, or Hsp104/70/40 and luciferase activity was measured after 90 minutes
of refolding. Daxx was able to efficiently renature luciferase when compared to lysozyme
and the buffer control. The Hsp104/70/40 system had very strong reactivation ability, as
expected (Glover, and Lindquist, 1998). However, when urea-denatured luciferase was
size fractionated, Daxx was not able to disaggregate the higher molecular weight
aggregates, which eluted at much earlier fractions than the heat-denatured luciferase
(Figure 3.8, A and B). Hsp104/70/40 was able to efficiently renature the urea-denatured
aggregates, as expected. These data indicate that Daxx can refold misfolded proteins,
but it cannot disaggregate higher molecular weight aggregates.
The PAH2 and acid-rich domains of Daxx are important for its activity
Preliminary data indicated that the acid-rich and PAH2 domains of Daxx were
most important for its activity toward luciferase. Based upon these findings, we
constructed mutants that either did not express both the PAH2 (residues 157-260) and
D/E (residues 414-505) domains (denoted as DaxxΔΔ), or only expressed the PAH2 or
D/E domain (Figure 3.9, A-E). All of these Daxx mutants were constructed in the same
vector as the full-length Daxx and purified using a similar method. When the GST tag
was cleaved from the PAH2 and D/E domains, the proteins were unable to be purified.
Thus, for those fragments we retained the GST tag and its activity was compared to fulllength Daxx with an intact GST tag.
When DaxxΔΔ was assayed for activity in a luciferase renaturation assay (as in
Figure 3.5), it was not able to renature heat-denatured luciferase (Figure 3.10A). When
the D/E or PAH2 domain were tested alone, they were unable to efficiently renature
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Figure 3.8. Daxx cannot renature higher molecular weight aggregates.
(A, B) Urea denatured luciferase (1 µM) was fractionated via gel filtration at 4ºC. The
elution profile was determined via western blotting (B). For refolding, column fractions in
the range of 2000 kDa-44 kDa were incubated with LRB, or 100 nM lysozyme, Daxx, or
Hsp104/70/40 supplemented with 10 mM ATP for 90 min at 25°C at which point
luciferase activity was determined (A).
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Figure 3.9. Purification of Daxx mutants.
(A) Schematic depicting structural domains of Daxx. PAH – paired amphipathic helices;
CC – coiled coil domain; D/E – acid-rich region; S/P/T – serine/proline/threonine-rich
region. Asterisks indicate deleted or isolated regions. (B-E) Coomassie-stained gels of
proteins purified after tandem-affinity purification and IEX chromatography. For smaller
fragments, GST-tag was retained due to loss of purification ability upon cleavage of tag.
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Figure 3.10. PAH2 domain and acid-rich region (D/E) are necessary for Daxx to
renature heat-denatured luciferase in vitro.
(A) Deletion of PAH2 and D/E regions leads to loss of renaturation ability. Heatdenatured luciferase (5 nM) was incubated with 125 nM GST, lysozyme, DaxxΔΔ, Daxx,
or Hsp104/70/40 supplemented with 10 mM ATP at 25ºC. (B) Mutants comprising only
the PAH2 (250 nM) or D/E (250 nM) region were tested either alone or in combination
for their ability to renature heat-denatured luciferase (5nM). For (B) and (C), luciferase
activity was read at the indicated times and expressed as fold change over an
undenatured control. Values represent means + SEM (n = 3).
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luciferase; however, when they were combined at equimolar ratios, there was a
synergistic reactivation effect upon denatured luciferase (Figure 3.10B). This suggests
that both domains are required for activity, but they are not sufficient on their own. To
confirm that these domains and full-length Daxx were able to interact directly with
luciferase, we purified Daxx, D/E and PAH2 fused only to GST. In an in vitro pull-down
assay, immobilized GST-Daxx, -D/E, and -PAH2, but not GST alone, were able to pull
down recombinant Flag-NLS-luciferase (Figure 3.11), indicating that full-length Daxx and
the D/E and PAH2 domains are able to directly interact with luciferase.
Daxx preferentially acts upon misfolded luciferase
To examine in vivo if Daxx had any effect on misfolded luciferase, we examined
whether Daxx could affect the protein levels of insoluble luciferase. Upon transfection of
Flag-Daxx with Flag-NLS-luciferase in H1299 cells, the cells were treated with
cycloheximide to inhibit new protein synthesis and the protein levels of insoluble
luciferase were analyzed (Figure 3.12, A and B). As shown by densitometry analysis, the
protein levels of insoluble luciferase decreased over time upon Daxx overexpression,
indicating that Daxx was able to solubilize the insoluble luciferase. We were unable to
detect a concomitant increase in the protein levels of soluble luciferase, most likely
because the insoluble fraction comprises a very small portion of the total luciferase.
Thus, any changes in the soluble fraction are not sensitive enough to be detected by
western blot.
To determine if this effect translated to enhanced binding of Daxx to misfolded
luciferase, a co-immunoprecipitation assay was performed. H1299 cells were transfected
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Figure 3.11. Daxx and Daxx fragments can bind to luciferase in vitro.
Recombinant Flag-NLS-luciferase purified from 293T cells was mixed with either lysis
buffer, GST, GST-Daxx, GST-PAH2, or GST-D/E purified from bacteria. Two different
amounts of Daxx and its mutants were used for immunoprecipitation. Input and IP were
analyzed by SDS-PAGE and western blot using anti-luciferase antibody for luciferase
and anti-GST antibody for GST, Daxx, and Daxx mutants. FL-full-length Daxx; D-acidrich region; P-PAH2 domain.
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Figure 3.12. Daxx can decrease the protein levels of insoluble luciferase.
(A) H1299 cells were transfected with Flag-NLS-luciferase with or without Flag-Daxx.
The cells were treated with CHX (50 µg/mL) for the indicated times. Both the
supernatant and pellet fractions were collected; however, only the pellet fraction was
analyzed for luciferase. Samples were analyzed via western blot and using densitometry
analysis (ImageJ), the luciferase to actin ratio was determined and plotted as a function
of time (B).
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with HA-Daxx with or without Flag-NLS-luciferase and subjected to heat shock as in
Figure 3.6. Upon heat shock, more Daxx precipitated with luciferase than in the control
condition (Figure 3.13A, lane 4 vs. 3). We confirmed that the heat shock of luciferase
was effective by testing the activity of the samples containing luciferase prior to
immunoprecipitation. The luciferase activity did decrease upon heat shock (Figure
3.13B). To further test this idea, we used an aggregation-prone luciferase mutant (FlagnDMFluc-GFP) (Gupta, Kasturi, et al, 2011). When wild-type (Flag-nFluc-GFP) and
mutant luciferase were immunoprecipitated, Daxx bound more strongly to the mutant
luciferase, even though it precipitated less effectively than the wild-type luciferase
(Figure 3.14). These results suggest that Daxx preferentially binds to misfolded
luciferase.
Daxx can solubilize p53 in vitro and in vivo
Since luciferase is not found in human cells, we sought to find a physiologically
relevant target of Daxx. It has been established by us and other groups that Daxx can
regulate p53 (Gostissa, Morelli, et al, 2004; Tang, Qu, et al, 2006; Tang, Agrawal, et al,
2013; Zhao, Liu, et al, 2004). We repeated a similar experiment to Figure 3.5B; we
purified Flag-p53 from mammalian cells and denatured it at 37ºC for 3-4 min to induce
misfolding (Figure 3.15A). Upon addition of increasing amounts of Daxx, p53 was
solubilized and shifted to the supernatant fraction (Figure 3.15A, lanes 3-6 vs. 1). The
addition of lysozyme seemed to increase the misfolding of p53 as more p53 was found
in the pellet fraction, similar to our result from Figure 3.5B and it was not able to
solubilize p53 as p53 was not detected in the supernatant fraction. To test if Daxx could
also stabilize p53 in vivo, we utilized p53 -/- Mdm2 -/- MEFs to eliminate the effect Daxx
has on Mdm2. When Flag-Daxx was transfected in increasing amounts with steady
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Figure 3.13 Daxx can preferentially associate with heat-denatured luciferase.
(A, B) Daxx preferentially binds to luciferase upon heat shock. H1299 cells were
transfected with HA-Daxx and Flag-NLS-luciferase as indicated. Cells were then treated
with CHX (50 µg/mL) for 30 min. Control samples were kept at 37°C for the duration of
the assay while heat shock and recovery samples were placed at 45°C for 30 min, after
which the recovery samples were placed back at 37°C for 3 h. Cell lysates were
incubated with anti-Flag M2 beads and input and IP samples were analyzed by western
blot (A). Luciferase activity was determined for samples with luciferase prior to
immunoprecipitation (B).
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Figure 3.14. Daxx preferentially associates with an aggregation-prone luciferase
mutant.
H1299 cells were transfected with HA-Daxx with Flag-nFluc-GFP or Flag-nDMFluc-GFP,
an aggregation-prone mutant of luciferase, as indicated. Cell lysates were incubated with
anti-Flag M2 beads and input and IP were analyzed by western blot. Asterisk indicates
non-specific band.
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Figure 3.15. Daxx can renature p53 in vitro and in vivo.
(A) Heat-denatured p53 aggregates (35 nM) were incubated at 25°C for 3 h with
lysozyme (100 nM), or Daxx (12.5 nM-100 nM). Reactions were then partitioned into
soluble and insoluble fractions via sedimentation at 17,000 x g for 15 min. (B) p53 -/Mdm2 -/- MEFs were transfected with increasing amounts of Flag-Daxx and two different
amounts of Flag-p53. Samples were analyzed via SDS-PAGE and western blot.
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states of Flag-p53, it was able to increase the protein levels of p53 (Figure 3.15B, lanes
2-3 vs. 1 and lanes 5-6 vs. 4). Together, these results suggest the Daxx is able to
stabilize p53, when Mdm2 is not present, both in vitro and in vivo.
Overall, these results indicate that Daxx has the ability to interact with misfolded
proteins and can assist in the renaturation of denatured substrates. This newly
discovered function for Daxx might have great implications in terms of finding an
explanation as to the many demonstrated functions of Daxx. It is possible that Daxx
interacts with so many proteins in order to regulate their folding. In-depth discussion of
these results can be found in chapter five.
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MATERIALS AND METHODS
Antibodies, plasmids, and proteins – Antibodies for the following proteins/epitopes were
purchased from the indicated sources: actin (A2066) and Flag (mouse monoclonal, M2,
free (F3165) and conjugated to beads (A2220), HRP-conjugated (A8592), rabbit
polyclonal (F7425)) (Sigma); GFP (JL-8, Clontech); Hausp/USP7 (A300, Bethyl
Laboratories, Inc.); HA conjugated to HRP (Roche); luciferase (OB09, Calbiochem);
Daxx (04-445, Millipore); p53 conjugated to HRP (DO-1, Santa Cruz Biotechnology).
Plasmids encoding HA- or Flag-tagged Daxx and luciferase for transient transfection
were made in pRK5. The luciferase plasmid was modified via addition of the SV40
nuclear localization signal (NLS) PKKKRKV and a Leu550-to-Ile mutation that abolishes
the lysosomal localization of luciferase. Flag-nFluc-GFP and Flag-nDMFluc-GFP were
modified from plasmids generously provided by Dr. S. Rayachaudhari (Gupta, Kasturi, et
al, 2011). GFP-Hsp70 was constructed in the pEGFP-C3 vector. pGEX-GST-Daxx-His
was constructed using a pGEX vector modified with a Tobacco Etch Virus cleavage site
(ENLYFQ) between the GST tag and the N-terminus of Daxx and using PCR for Daxx
and the 6xHis tag. All Daxx mutants were constructed similarly into the same modified
pGEX vector. DaxxΔΔ was constructed using the QuikChange Site Directed
Mutagenesis Kit (Agilent). Hsp104 was a kind gift from the lab of Dr. James Shorter. Hsp
70 and 40 were purchased from Enzo Life Sciences.
Protein purification – The pGEX-GST-Daxx-His vector was transformed into Rosetta 2
(Novagen) competent cells and resulting transformants were grown in 20 L LB medium,
supplemented with 100 µg/mL ampicillin, for 14-16 h until they reached an OD600 of 0.5.
Cultures were induced with 0.1-0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for
4 h at 27ºC. Cells were collected via centrifugation and the pellet was lysed with Ni-NTA
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lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole at pH 8.0 containing
fresh 1 mM PMSF, 2 mM DTT, and 1 mg/mL lysozyme) followed by sonication for 20
min. Lysates were either stored at -80ºC until needed or immediately incubated with
GST beads (GE Healthcare) for 4 h to overnight at 4ºC. Beads were then washed with
IP lysis buffer (20 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP40, and 10% glycerol) twice, IP lysis buffer containing 0.5 M KCl once, IP lysis buffer
containing 1.0 M KCl once, IP lysis buffer twice and AcTEV (Invitrogen) buffer (50 mM
Tris-HCl at pH 8.0 and 0.5 mM EDTA) once. The beads were then incubated at 25ºC for
2-3 h with AcTEV protease (Invitrogen) in AcTEV buffer supplemented with 25 mM DTT.
The supernatant was collected and incubated with Ni-NTA beads (Invitrogen) for 2-4 h at
4ºC. The beads were then washed with Ni-NTA wash buffer (50 mM NaH2PO4, 10 mM
NaCl, and 10 mM imidazole at pH 7.0) three times and eluted with Ni-NTA elution buffer
(50 mM NaH2PO4, 10 mM NaCl, and 500 mM imidazole at pH 7.0) for 1 h at 4ºC. The
eluate was collected and subjected to IEX chromatography using a Mono Q column (GE)
developed at a flow rate of 1 mL/min at pH 7.0. The protein was eluted from the column
using a linear gradient of 10 mM – 1 M NaCl. Fractions were flash-frozen and stored at 80ºC until needed. Proteins were purified to apparent homogeneity as determined by
SDS-PAGE and Coomassie staining and the identity of specific bands was confirmed via
mass spectrometry analysis. When GST-tag cleavage was not desired, GST beads were
eluted with 35 mM reduced glutathione (GSH; Sigma) at pH 7.5 for 1 h at 4ºC and the
rest of the purification was the same as above. Flag-tagged p53 was purified from 293T
cells using (10) 10 cm plates. Cells were transfected with via calcium phosphate
transfection method. 16 h later, cells were harvested using IP lysis buffer. Lysates were
spun down at 17,000 x g for 15 min at 4ºC and supernatants were incubated with anti-
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Flag mAb beads for 4 h or overnight at 4ºC. After extensive washing, Flag-p53 was
eluted using 3x Flag peptide (Sigma) for 1 h at 4ºC.
Luciferase assays – For renaturation assays, firefly luciferase (Sigma) was heat
denatured at 42ºC for 10-15 min and distributed to reactions at a final concentration of 5
nM in luciferase refolding buffer (LRB: 25 mM HEPES-KOH at pH 7.4, 150 mM KAOc,
10 mM MgAOc, and 10 mM DTT). For these reactions, GST and lysozyme were used as
negative controls, Hsp104/70/40 was supplemented with ATP and ATP regeneration
solution (Boston Biochem) and used as a positive control, and Daxx and mutants were
added without ATP. For prevention of denaturation assays, luciferase (5 nM) was
concurrently incubated with proteins at 42ºC and readings were taken at specified times.
In both cases, triplicate reactions were made and luciferase readings were taken using
the Luciferase Assay System (Promega) at indicated times using a Monolight 2010
luminometer (Analytic Luminescence Laboratory). Activity was converted to fold change
over native control via comparison to known quantities of an undenatured luciferase
control.
Sedimentation assays – Luciferase and p53 were denatured at 42ºC or 37ºC for 15 min
or 5 min, respectively, and then distributed to reactions containing buffer (LRB for
luciferase; PBS with 5 mM DTT for p53), lysozyme as a negative control, or Daxx. After
3 h, the reactions were centrifuged at 17,000 x g for 15 min at 4ºC. The pellet and
supernatant fractions were then resuspended in sample buffer and analyzed by SDSPAGE.
Gel filtration – Luciferase (100 µM) was unfolded in 4 M Urea for 25 min at 30ºC and
diluted 50-fold into cold LRB. Aggregates were then spun down at 17,000 x g for 10 min
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at 4ºC. Then, 0.5 mL was loaded onto a 1 x 30 cm Superose 6 column (GE) equilibrated
in LRB. Fractions (0.4 mL) were collected 15 min post-injection at a flowrate of 0.4
mL/min. For heat-denatured luciferase, luciferase (1 µM) was incubated at 42ºC for 20
min or until the luciferase activity was at least two magnitudes less than native control.
Fractions were collected as for urea-denatured luciferase. For refolding in both
instances, column fractions in the range of 2000 kDa-44 kDa were incubated with LRB,
lysozyme (100 nM), Daxx (100 nM), or Hsp104/70/40 (100 nM) with ATP (10 mM) and
incubated at 25°C. Luciferase activity was determined after 90 min of refolding.
In vivo luciferase assay – H1299 cells were transfected with Flag-NLS-luciferase and
either Flag-pRK5, Flag-Daxx, or GFP-Hsp70. After 16 h, cells were split in triplicate into
24-well plates. 16 h later, cycloheximide (CHX) (50 µg/mL) was added to the cells for 30
min. The heat shock and recovery plates were placed at 45ºC for 30 min after which the
recovery plate was placed back at 37ºC for 3 h. Cells were lysed using Passive Lysis
Buffer (Promega) and read using the Luciferase Assay System (Promega). Readings
were normalized to the control sample of each group.
Immunoprecipitation and western blot – Transfections were carried out using
Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen) according to the
manufacturer’s instructions. After treatments were complete, cells were lysed in IP lysis
buffer, supernatant (50 mM Tris at pH 8.8, 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, and
fresh 2 mM DTT, 250 IU/ml benzonase (Sigma), 1 mM PMSF, and 1x complete protease
inhibitor cocktail) or pellet buffer (20 mM Tris at pH 8.0, 15 mM MgCl2, and fresh 2 mM
DTT, 250 IU/ml benzonase, 1 mM PMSF, and 1x complete protease inhibitor cocktail)
for fractionation analysis. Flag-NLS-luciferase was immunoprecipitated with anti-Flag
mAb beads and analyzed by western blot using anti-Luc antibody (1:500) for luciferase
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input, Flag-HRP antibody (1:1000) for luciferase IP, and HA-HRP antibody (1:5000) for
Daxx input and IP.
In vitro binding - Flag-NLS-luciferase was purified from 293T cells using anti-Flag mAb
beads for 4 h to overnight at 4ºC and eluted with 3x Flag peptide for 1 h at 4ºC. GST,
GST-Daxx, -D/E, and -PAH2 were constructed into pGEX with only a GST tag and
purified similarly to pGEX-GST-Daxx-His proteins with omission of the His purification
and IEX chromatography steps. Briefly, cleared lysates were incubated with GST beads
for 4 h to overnight at 4ºC. After extensive washing, the beads were eluted with 30mM
GSH at 4ºC for 1 h. Mixtures of luciferase (5 nM) and Daxx fragments were incubated at
4ºC for 2 h after which a portion was taken for input. The rest of the reactions were
incubated with GST beads previously blocked with 3% BSA for 1 h at 4ºC. Samples
were washed three times with IP lysis buffer and beads were resuspended in sample
buffer and analyzed by SDS-PAGE and western blot. Input and IP samples were blotted
with luciferase antibody and anti-GST antibody for GST, Daxx and Daxx mutants.
Quantitative RT-PCR analysis – Total RNA was isolated from cells using TRIzol
(Invitrogen). Reverse transcription was performed using the First Strand cDNA Synthesis
Kit (Marligen Biosciences). Primers used for luciferase amplification are as follows:
forward primer 5’ – CAA CTG CAT AAG GCT ATG AAG AGA – 3’; reverse primer 5’ –
ATT TGT ATT CAG CCC ATA TCG TTT – 3’.
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CHAPTER 4: THE ROLE OF DAXX IN CDK6 REGULATION
INTRODUCTION
Daxx has the ability to regulate cellular proliferation through its cell-cycle
dependent expression patterns and functions. Daxx is translocated to heterochromatin
during S phase of the cell cycle via association with ATRX. It is released from ATRX
during G2 phase, suggesting that the Daxx-ATRX interaction is important for S phase
progression. Furthermore, Daxx-deficient cells display an accelerated S phase (Ishov,
Vladimirova, and Maul, 2004). Another study uncovered a role for Daxx in cell cycle
progression where depletion of Daxx led to perturbations in the duration of mitotic stages
(Giovinazzi, Lindsay, et al, 2012). They found that Daxx-depleted cells displayed a
stabilization of cyclin B and though there was a faster progression through prophase,
there was a prolongation of prometaphase/metaphase, indicating that Daxx is required
for normal mitosis. Preliminary data from our lab indicate that Daxx knockdown
abrogates cell growth in a p53-independent and -dependent manner (Figure 4.1, A and
B). When Daxx is stably knocked down using shRNA in U2OS or the p53-null cell line
H1299, there is an abrogation of proliferation. Decrease in cellular proliferation in the
p53 wild-type cells can be explained by the role of Daxx in Mdm2 stabilization (Tang,
Qu, et al, 2006); however, the mechanism by which Daxx can regulate proliferation
independent of p53 remains elusive. While investigating targets of Daxx using
microarray analysis in human colon carcinoma (HCT116 p53 +/+) cells, we found that in
Daxx-depleted cells, a cell cycle regulator, cyclin-dependent kinase 6 (Cdk6), was the
most strongly downregulated gene (Figure 4.2).
Cdk6 was first identified as a novel member of the vertebrate family of Cdk1
kinases (Meyerson, Enders, et al, 1992). It was found to possess kinase activity toward
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Figure 4.1. Daxx-depletion leads to abrogation of cell growth in a p53-independent
manner.
(A, B) U2OS and H1299 (p53-deficient) cells were used to create stable cell lines
expressing pLKO.1 or Daxx-shRNA and assessed for proliferation ability (n = 2) (A) and
protein expression (B).
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Figure 4.2. Heat map depicting microarray analysis of Daxx-depleted HCT116 p53
+/+ cells.
Yellow box highlights downregulation of Cdk6 expression upon Daxx silencing. Figure
courtesy of Aaron Stonestrom.
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pRb and partner with the G1 phase cyclins, allowing for progression through the cell
cycle (Meyerson, and Harlow, 1994). Cdk6 shares almost 71% homology with Cdk4 and
both are able to bind to cyclins D1, D2, and D3 during G1 phase to phosphorylate pRb
(Grossel, and Hinds, 2006). Both are ubiquitously expressed and are generally
considered functionally redundant (Grossel, and Hinds, 2006). However, recent
evidence indicates that Cdk6 has functions distinct from those of Cdk4 and can have a
role beyond cellular proliferation.
Many studies have emerged implicating Cdk6 as a regulator of differentiation in a
variety of cell types. For example, Cdk6 can block differentiation of murine
erythroleukemia (MEL) cells and its downregulation is required for MEL cells to reinitiate
differentiation (Matushansky, Radparvar, and Skoultchi, 2003). The entry of MEL cells
into terminal differentiation is accompanied by a decrease in Cdk2 followed by a decline
in Cdk6 activity and inhibitors against Cdk2 and Cdk6 can trigger differentiation.
Importantly, inhibitors against Cdk4 or an inhibitor-resistant form of Cdk4 cannot cause
differentiation of these cell types, providing a functional difference between Cdk6 and
Cdk4 (Matushansky, Radparvar, and Skoultchi, 2000). Further, it was shown that Cdk6
downregulation is essential for BMP-2-mediated osteoblast differentiation (Ogasawara,
Kawaguchi, et al, 2004). Overexpression of Cdk6, but not Cdk4, led to inhibition of
differentiation of the osteoblasts. Interestingly, this study found that Cdk6 did not
influence the proliferation of the osteoblasts and had no effect on their progression
through the cell cycle. Finally, Cdk6 is essential for Notch-dependent T-lineage survival,
proliferation, and differentiation (Hu, Deshpande, et al, 2009). Cdk6, though ubiquitously
expressed, is most abundant in lymphoid organs (Meyerson, Enders, et al, 1992;
Meyerson, and Harlow, 1994). It has predominant expression in hematopoietic cell types
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and is overexpressed in human T-cell lymphoblastic leukemia (T-ALL), suggesting a role
for Cdk6 in thymocyte malignancies (Chilosi, Doglioni, et al, 1998; Della Ragione,
Borriello, et al, 1997). The study by Hu, et al found that Cdk6 -/- mice had a reduction in
thymocyte numbers in all compartments, consistent with the observation that Cdk6 -/mice have defective thymic development (Malumbres, Sotillo, et al, 2004). It was found
that Cdk6 is required for Notch-dependent proliferation, survival and differentiation.
Together, these results suggest that Cdk6 has cell cycle-independent functions.
While Cdk6 is presumed to be a promoter of cellular proliferation, Cdk6 can also
inhibit proliferation in a specific subset of cells. NIH 3T3 cells that stably overexpress
Cdk6 proliferated at a significantly slower rate than when the cells concurrently
overexpressed Cdk6 and a dominant negative form of Cdk6, indicating that Cdk6 was
inhibiting cell growth (Nagasawa, Gelfand, and Lucas, 2001). Additionally, Cdk6 can
inhibit the proliferation of some human mammary epithelial (HMEC) cells (Lucas,
Domenico, and Gelfand, 2004). This study showed that breast-tumor derived cell lines
had reduced levels of Cdk6 protein while primary HMECs had high levels of Cdk6.
Overexpression of Cdk6 in the tumor cell lines led to reduced growth rates; when ectopic
expression of Cdk6 was lost, they were able to proliferate more rapidly.
The roles of Cdk6 in differentiation and anti-proliferation indicate that Cdk6 is
more than a mediator of the cell cycle. Understanding the regulation of Cdk6 would
provide new insight into how cellular differentiation occurs and how cancer cells
downregulate the growth-inhibitory effects of Cdk6 to promote proliferation. Based upon
our microarray analysis showing that Cdk6 was strongly downregulated upon Daxx
depletion and that Daxx may have p53-independent functions related to cellular
proliferation, we focused our efforts on the regulation of Cdk6 by Daxx.
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RESULTS
Daxx depletion leads to lower protein levels of Cdk6 in a variety of cell lines
To confirm the microarray result where Daxx depletion in HCT116 p53 +/+ cells
led to downregulation of Cdk6 (Figure 4.2), an array of cancer cell lines were treated
with control or Daxx siRNA and assessed for Cdk6 expression. When Daxx was
depleted in U2OS or isogenic HCT116 p53 +/+ and p53 -/- cells, Cdk6 protein levels
were also dramatically reduced (Figure 4.3, A and B). This effect was also seen when
the primary cell lines, IMR90 (human fetal lung fibroblasts) and MEFs (mouse embryonic
fibroblasts) were used for analysis (Figure 4.3, C and D). Conversely, overexpression of
Daxx in HCT116 p53 +/+ cells correlated with higher Cdk6 protein levels, albeit it was
not a very robust effect (Figure 4.4A). A rescue experiment was performed using
HCT116 p53 +/+ cells where Daxx was stably knocked down using shRNA. After
establishing the stable cell line, Flag-Daxx was transiently overexpressed and Cdk6
levels were assessed. Upon expression of exogenous Daxx, Cdk6 levels were higher
than when Daxx was depleted indicating that Daxx can modulate Cdk6 protein levels
(Figure 4.4B, lanes 2-4 vs. 1).
To determine if the effect of Daxx was specific to Cdk6, we examined the
expression of various cell cycle markers upon Daxx depletion. We examined the levels
of Cdk2, Cdk4, cyclin D1, and Rb (Figure 4.5, A and B) in a variety of cancer cell lines.
These proteins were minimally affected by Daxx knockdown suggesting that the effect of
Daxx was specific for Cdk6.
Daxx affects transcription of Cdk6
To test if Daxx was regulating the stability of Cdk6 via a degradation-dependent
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Figure 4.3. Cdk6 protein levels decrease upon Daxx silencing.
U2OS (A) HCT116 p53 +/+ and -/- (B) and IMR90 (C) cells were treated with control or
Daxx siRNA and analyzed for Cdk6 expression via western blot. (D) Daxx +/+ or Daxx -/MEFs were assessed for Cdk6 expression via western blot.
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Figure 4.4. Daxx overexpression increases Cdk6 protein levels.
(A) Flag-Daxx was transfected in HCT116 +/+ cells and analyzed by western blot for
Cdk6. Daxx levels were assessed using anti-Daxx antibody. (B) HCT116 p53 +/+ cells
stably expressing Daxx shRNA were transfected with increasing amounts of Flag-Daxx
and assessed for Cdk6 levels. Daxx expression was confirmed separately by anti-Daxx
and anti-Flag antibodies.
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Figure 4.5. Daxx does not affect protein levels of other cell cycle regulators.
(A) U2OS, Saos-2, and HCT116 p53 +/+ cells were treated with control or Daxx siRNA
and analyzed by western blot for Cdk2 and Cdk6 expression. (B) Isogenic HCT116 p53
+/+ and p53 -/- cells were Daxx-depleted and assessed for Rb, cyclin D1, and Cdk4
expression.

88

mechanism, we used MG132, a proteasome inhibitor, in combination with Daxx siRNA
and examined Cdk6 protein levels in various cancer cell lines. We analyzed Mdm2 levels
as an internal control for the effectiveness of MG132 treatment, as Mdm2 is very
sensitive to proteasome-mediated degradation. We observed that with MG132
treatment, Mdm2 levels increased indicating that MG132 was inhibiting the proteasome
and in turn Mdm2 degradation (Figure 4.6). Daxx silencing led to lower Cdk6 levels, yet
Cdk6 levels were only marginally altered in the presence of MG132, regardless of Daxx
siRNA treatment. This is not completely unexpected, as Cdk levels remain fairly constant
during the cell cycle (Sherr, 2000; Vermeulen, Van Bockstaele, and Berneman, 2003).
This result suggests that Daxx is not regulating Cdk6 levels via a degradation-dependent
mechanism.
To further test if Daxx was controlling the stability of Cdk6 protein, cycloheximide
was used to inhibit new protein synthesis in HCT116 p53 -/- cells to determine changes
in Cdk6 half-life in the absence of Daxx. When Daxx was silenced via siRNA treatment,
there were lower overall levels of Cdk6. To fairly compare the half-life of Cdk6 upon
Daxx knockdown, we analyzed two different exposures of Cdk6 where the zero hour
time points appeared most equal (Figure 4.7, lanes 5-8 vs. 1-4). After comparison of the
different exposures, it was clear that Daxx depletion had little effect on the half-life of
Cdk6. Together, these results indicate that Daxx does not affect the protein stability of
Cdk6.
To further elucidate the mechanism by which Daxx was affecting Cdk6 protein
levels, we examined if Daxx affected Cdk6 transcription. Human cervix adenocarcinoma
(HeLa) and H1299 cells were treated with Daxx siRNA and analyzed via western blot,
RT-PCR and quantitative RT-PCR (Figure 4.8, A-C). Daxx-depleted cells displayed
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Figure 4.6. Daxx does not affect protein stability of Cdk6.
H1299, HeLa, and HCT116 p53 +/+ were treated with control or Daxx siRNA. 16 h later,
cells were treated with MG132 (20 µM) for 4 h. Samples were harvested and analyzed
via western blot.
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Figure 4.7. Daxx does not affect half-life of Cdk6.
HCT116 p53 -/- cells were depleted of Daxx using siRNA. 16 h later, cells were treated
with CHX (50 µg/mL) for the indicated times. After harvesting and lysis, samples were
analyzed for Cdk6 expression via western blot. Two different exposures of Cdk6 are
shown where band intensity at the zero time points is most comparable.
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Figure 4.8. Daxx affects transcription of Cdk6.
H1299 and HeLa cells were treated with control or Daxx siRNA and assessed for protein
(A) and mRNA levels using RT-PCR (B) and qPCR (C).
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lower levels of Cdk6 protein (Figure 4.8A) and mRNA (Figure 4.8, B and C) suggesting
that Daxx was able to regulate the transcription of Cdk6. To expand the transcriptional
regulatory role of Daxx, we performed chromatin immunoprecipitation (ChIP) to assess
whether Daxx associates with the endogenous Cdk6 promoter (Figure 4.9). For this
experiment, HCT116 p53 +/+ cells were subject to chemical crosslinking followed by
immunoprecipitation of Daxx and analysis of associated DNA via qPCR using genespecific primers (see materials and methods for sequences). The results are shown as
relative input units to account for background signal and input chromatin. The ChIP
assay reveals that Daxx bound to the Cdk6 promoter with some specificity, as it was not
associated with the actin promoter. p53 was immunoprecipitated as a positive control
and it bound to the p21 promoter, as expected. Daxx signal was most enriched at the 700 bp region of the Cdk6 promoter. Interestingly, there is a potential binding NF-κB
binding site at this region of the Cdk6 promoter (Cram, Liu, et al, 2001) and Daxx has
previously been shown to modulate transcription of NF-κB target genes (Michaelson,
and Leder, 2003; Park, Lee, et al, 2007). We also observed enrichment of Daxx at the -1
kb and +1 kb regions; it is possible that Daxx can bind in multiple areas of the Cdk6
promoter.
Daxx depletion does not affect the cell cycle
We next attempted to determine the consequence of Daxx knockdown and
subsequent decrease of Cdk6 levels on cellular proliferation by using HCT116 p53 +/+
and p53 -/- cells (Figure 4.10, A-C). Stable cell lines were created where Daxx was
silenced using shRNA and after establishment of the stable cell lines, proliferation
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Figure 4.9. Daxx can bind to promoter of Cdk6.
Chromatin from HCT116 p53 +/+ cells was immunoprecipitated using anti-Daxx serum,
anti-p53 antibody, and their respective controls. Different regions upstream or
downstream of the Cdk6 transcription start site were amplified using region-specific
primers and analyzed via qPCR. Samples are represented as relative input units by
comparing fold enrichment to signal amplification of input samples. PI – pre-immune
serum.
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Figure 4.10. Daxx depletion and analysis of cellular proliferation.
(A-C) Stable cells lines expressing Daxx shRNA were established in HCT116 p53 +/+
and HCT116 p53 -/- cells. Cell lines were analyzed for proliferation (A and B) and protein
levels of Daxx and Cdk6 (C).
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assays were performed. When Daxx was stably knocked down in HCT116 p53 +/+ cells,
cellular proliferation occurred at a slower rate (Figure 4.10A); however, the same effect
was not observed in HCT116 p53 -/- cells despite decreased levels of Cdk6 protein in
the Daxx-depleted cells (Figure 4.10, B and C). Data from Figure 4.1 indicated that when
Daxx was knocked down, there was a proliferative defect regardless of p53 status
suggesting that this current result (Figure 4.10) may be cell type-specific. Based upon
this observation, we sought to examine if Daxx depletion was able to alter the cell cycle
profile. We used flow cytometry and propidium iodide (PI) staining to assess the cell
cycle profiles of cells treated with control or Daxx siRNA. When Daxx was depleted in
HCT116 p53+/+ or p53 -/- cells, we saw no difference in cell cycle profile compared to
cells with control siRNA (Figure 4.11A). Daxx knockdown was confirmed via western
(Figure 4.11B). These results suggest that while Daxx can affect the transcription of
Cdk6, it is unable to elicit major changes in cellular proliferation or the duration of
different stages of the cell cycle due to downregulation of Cdk6.
While we were able to confirm that Daxx depletion led to lower levels of Cdk6 at
the protein and mRNA level and that Daxx is able to bind to the promoter of Cdk6, we
were not able to establish a physiologically relevant outcome for this effect. Future
studies will determine the mechanism and consequence of this newly identified function
of Daxx. A discussion of the current results can be found in chapter five.
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Figure 4.11. Daxx silencing does not affect cell cycle profile.
HCT116 p53 +/+ and HCT116 p53 -/- cells were treated with control and Daxx siRNA. 16
h later, cells were stained for PI and assessed for cell cycle distribution (A). Western
analysis confirms Daxx knockdown. Hsp70 is shown as loading control (B).
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MATERIALS AND METHODS
Antibodies - Antibodies for the following proteins/epitopes were purchased from the
indicated sources: actin (A2066), tubulin (T4026), and Flag (mouse monoclonal, M2,
(F3615) (Sigma); Daxx (M-112) p53 (DO-1) (Santa Cruz Biotechnology); Cdk6 (DCS83)
and Cyclin D1 (DCS6) (Cell Signaling); GFP (JL-8, Clontech); Mdm2 (Ab-1,Calbiochem);
Hsp70 (C92F3A-5, Enzo Life Sciences). Antibodies for Cdk2 and Cdk4 were kind gifts
from the lab of Dr. J. Alan Diehl. Antibody for Rb was a kind gift from the lab of Dr. Judy
Meinkoth.
Microarray analysis – Note: Performed by Aaron Stonestrom. HCT116 p53 +/+ cells
were transfected with control or Daxx siRNA and total RNA was isolated using TRIzol
(Invitrogen). Samples were then sent to the Penn Molecular Profiling Facility for analysis.
Briefly, total RNA was converted to first-strand cDNA using Superscript II reverse
transcriptase primed by a poly(T) oligomer that incorporated the T7 promoter. Secondstrand cDNA synthesis was followed by in vitro transcription for linear amplification of
each transcript and incorporation of biotinylated CTP and UTP. The cRNA products were
fragmented to 200 nucleotides or less, heated at 99ºC for 5 min and hybridized for 16 h
at 45ºC to microarrays. The microarrays were then washed at low (6X SSPE) and high
(100mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin.
Fluorescence was amplified by adding biotinylated anti-streptavidin and an additional
aliquot of streptavidin-phycoerythrin stain. A confocal scanner was used to collect
fluorescence signal at 3um resolution after excitation at 570 nm. The average signal
from two sequential scans was calculated for each microarray feature. Affymetrix
Microarray Suite 5.0 was used to quantitate expression levels for targeted genes; default
values provided by Affymetrix were applied to all analysis parameters.
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Quantitative RT-PCR analysis - Total RNA was isolated from cells using TRIzol
(Invitrogen). Reverse transcription was performed using the First Strand cDNA Synthesis
Kit (Marligen Biosciences). Primers used for Cdk6 amplification are as follows: forward
primer 5’ – GTA ATC GTG TCT GTG TTG AG – 3’; reverse primer 5’ – TCT GCA CCC
GCA CGC GCT TC – 3’.
Cell culture, transfections, and western blot - All cells were obtained from the ATCC and
maintained in Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. To generate lentiviruses expressing control and
Daxx shRNA, which were cloned into the pLKO.1 backbone, phoenix cells were
transfected with pREV, pGAG, and pVSVG with either control (pLKO.1) or Daxx shRNA.
48-72 h after transfection, the lentivirus-containing medium was used to infect HCT116
p53+/+ and p53 -/- cells in the presence of 8 µg/mL polybrene. The infected cells were
selected in the presence of 2 µg/ml puromycin for 4-5 days. Transient transfections were
carried out using Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen)
according to the manufacturer’s instructions. MG132 (20 µM) was applied to cells for 4 h,
when required. To harvest cells, briefly, cells were scraped in IP lysis buffer and spun
down at 17,000 x g for 15 min at 4ºC. After protein concentration was determined (BioRad), samples were resolved by SDS-PAGE. Samples were blotted with anti-Daxx
(1:5000), anti-Cdk6 (1:200), anti-tubulin (1:5000), and anti-actin (1:5000) antibodies.
Cellular proliferation assay – After stable cells lines expressing Daxx shRNA were
selected and assessed for Daxx knockdown, 5,000 cells per well were seeded in 24well, 12-well, and 6-well plates and 6 and 10 cm dishes. Cells were seeded in duplicate
for each condition and counted in successively larger plates to prevent them from
reaching confluency.
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Cell cycle analysis – After Daxx silencing for 24 h, cells were collected via centrifugation
and washed twice with PBS and then fixed with 70% ethanol overnight at −20 °C. Cells
were then treated with 0.1% Triton X-100 and 50 µg/mL RNase A for 30 min at 37 °C
followed by PI staining. Cell cycle distribution was analyzed using a FACScalibur flow
cytometer (BD Biosciences). The data were analyzed using Flow Jo software (Tree
Star).
Chromatin Immunoprecipitation (ChIP) – ChIP was performed using the ChIP-IT Express
kit according to manufacturer’s instructions (Active Motif). HCT116 p53 +/+ cells were
washed with PBS and crosslinked with a 1% formaldehyde solution for 10 min at 25ºC.
Crosslinking was quenched by the addition of 125 mM glycine. Cells were collected
using the provided cell-scraping solution supplemented with fresh 1 mM PMSF. Lysates
were sonicated to generate DNA fragments with an average size below 1,000 base pairs
and followed by immunoprecipitation with anti-Daxx serum, pre-immune serum, anti-p53
(DO-1), an isotype-matching control and provided Protein G magnetic beads at 4ºC for
at least 4 h or overnight. Chromatin was eluted using provided elution buffer for 15 min
at 25ºC and crosslinks were reversed using reverse cross-linking buffer. Proteinase K
was added to the samples and incubated at 37ºC for 1 h. qPCR was performed on the
eluted chromatin. The primer pairs were: -1 kb forward: GCT GTG CAA TGT GTT TGT
GTT, -1 kb reverse: ACC TCC CAG GCT CAA CCT AT; +1 kb forward: ATG GAG GGA
TGG TTG CTA GA, +1 kb reverse: GCA CAG CTC TCT GAA AGC AA; 0 kb forward:
CGG CCA ATT GTT GAA TGA GT, 0 kb reverse: TGG TGC TTC TTA TTT GCA ACCA;
-700 bp forward: TAA GTG CCC TTT GCA GGT G, -700 bp reverse: TGG TGT AGC
CTA AGC CTC CT; -300 bp forward: CTC CAC TTC CCA GGT TCA AG, -300 bp
reverse: AAC GTG GTG AAA CCC TGT GT; p21 forward: CTG AAA ACA GGC AGC
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CCA AG, p21 reverse: GTG GCT CTG ATT GGC TTT CTG.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
In the preceding chapters, I have demonstrated that Daxx is involved in p53
regulation, protein folding, and Cdk6 modulation; an array of diverse activities that
further add to the complex functions of Daxx within the cell and may also provide a
biochemical unity for these functions. These findings further our understanding of the
anti-apoptotic and transcriptional functions of Daxx while providing a novel role for Daxx
in protein folding. The remainder of this chapter discusses the implications of these
findings and provides ideas to expand these observations.
The Role of Daxx in p53 Regulation
The accumulation of p53 in response to cellular stress is highly dependent upon
the destabilization of its main negative regulator, Mdm2. The mechanism of Mdm2
inactivation upon stress signaling is not well understood. In this section, we showed that
Daxx is phosphorylated by ATM at Ser564 in response to DNA damage. This
phosphorylation event hinders Daxx association with Mdm2 allowing for destabilization
of Mdm2 and subsequent p53 activation (Figure 5.1). The stabilization of Mdm2 by the
Daxx S5645A mutant is Hausp-dependent, confirming our previous study where wildtype Daxx mediated stabilization of Mdm2 was Hausp-dependent (Tang, Qu, et al,
2006).
ATM is activated upon DNA damage and leads to the phosphorylation of various
substrates either directly or via activation of downstream kinases. We have discovered
Daxx as a novel substrate of ATM. The finding that ATM not only phosphorylates Mdm2
and p53 in times of cellular stress, but also their upstream regulator, Daxx, indicates that
the cell possesses an intricate signaling network to maintain genomic stability by
activating p53. It has previously been shown that ATM-mediated phosphorylation of
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Figure 5.1. Phosphorylation of Daxx by ATM upon DNA damage allows for p53
activation.
Upon DNA damage, ATM phosphorylates Mdm2 and p53. Our finding extends its
phosphorylation activity to Daxx, as well. This event hinders the association between
Daxx and Mdm2 thereby disrupting the Daxx-Mdm2-Hausp complex, allowing for p53
activation.
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Mdm2, and a related protein MdmX, reduces their affinity for Hausp, ultimately leading to
p53 activation (Meulmeester, Maurice, et al, 2005). However, it is also known that Hausp
deubiquitinates p53, which is important for p53 stabilization (Li, Chen, et al, 2002).
These findings fit a model whereby the phosphorylation of Daxx upon DNA damage
leads to dissociation of Mdm2 from itself and Hausp, allowing Hausp to direct its
deubiquitinase activity toward p53 instead of Mdm2. Therefore, Daxx may provide
Hausp with substrate specificity.
A major shortcoming of the present study was the lack of a strong phenotype
upon the introduction of the Daxx S564A mutant. It is possible that the endogenous wildtype Daxx masked the effect of the mutant Daxx and that Mdm2 stabilization was
already at a maximum. We attempted to circumvent this issue via the creation of stable
cell lines that expressed shRNA against Daxx while also stably overexpressing either
wild-type or mutant Daxx; however, we were unsuccessful in our attempts. It is possible
that a Daxx-depleted background would allow for the effects of the mutant to become
more apparent allowing us to see stronger downstream effects of p53 activation such as
cell cycle arrest, apoptosis, or the induction of other p53 targets.
The discovery that Daxx is a novel target for ATM sheds further light on the many
signaling pathways that govern p53 activation. Daxx appears to be the central
component of the interaction between Mdm2 and Hausp, both of which are critical
regulators of p53. Daxx may be a promising therapeutic target for tumors that retain wildtype p53, perhaps via the overexpression of Mdm2. The possibility cannot be excluded
that the Daxx-Mdm2-Hausp complex not only regulates p53, but also other substrates of
Mdm2. For example, the p53 homologs, p63 and p73 have been shown to interact with
Mdm2 (Zdzalik, Pustelny, et al, 2010) with Mdm2 being able to inhibit p63 transcriptional
activity and p63-mediated induction of apoptosis (Kadakia, Slader, and Berberich, 2001).
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Thus, the stabilization of Mdm2 by Daxx not only has important implications for p53
regulation, but also for other potential substrates of Mdm2, many of which may have
unexplored tumorigenic properties.

Future Directions
Another responder to DNA damage, besides ATM, is ATR (ataxia telangiectasia
and Rad3-related protein). ATR mainly responds to single-stranded DNA, while ATM
responds to double-strand breaks in DNA or chromatin disruption (Sancar, LindseyBoltz, et al, 2004). In some experiments, basal Daxx phosphorylation exists even without
the presence of ATM or a DNA damaging agent. This can be explained in two ways:
first, cancer cells may possess a basal amount of DNA damage leading to the activation
of ATM causing phosphorylation of Daxx. Second, Daxx may be a substrate of ATR, as
it is known that ATR phosphorylates p53 upon DNA damage suggesting that it may also
target upstream regulators of p53 (Matsuoka, Ballif, et al, 2007; Tibbetts, Brumbaugh, et
al, 1999). While ATM ablation in the study by Tang, et al did generally prevent the
dissociation of the Daxx-Mdm2-Hausp complex upon DNA damage, it was not able to
completely keep the complex from disrupting (Tang, Qu, et al, 2006). This indicates that
another upstream regulator may be targeting the complex; a potential candidate is ATR.
We could perform in vitro kinase assays with ATR to determine if ATR can directly
phosphorylate Daxx. Since the consensus sites of ATM and ATR are the same, it is
possible that ATM and ATR are acting at the same site to phosphorylate Daxx.
Besides examining the regulation of Daxx, we should also analyze how Daxx
may affect other potential components of this complex. It is believed that Mdm2 exists
predominantly

as

a

heterodimer

with

a

related

protein,

MdmX,

and

this

heterodimerization increases the E3 activity of Mdm2 toward p53 (Kawai, Lopez105

Pajares, et al, 2007; Linares, Hengstermann, et al, 2003). MdmX is also able to prevent
Mdm2 from degradation (Stad, Little, et al, 2001; Tanimura, Ohtsuka, et al, 1999). MdmX
shares a few functional characteristics with Mdm2 in that it is overexpressed in many
tumors that retain wild-type p53, it is able to inhibit the transactivation of p53, and MdmX
-/- mice display embryonic lethality that can be rescued by simultaneous p53 deletion
(Danovi, Meulmeester, et al, 2004; Finch, Donoviel, et al, 2002; Migliorini, Lazzerini
Denchi, et al, 2002; Okamoto, Taya, and Nakagama, 2009). Due to their similarity in
function, it would be interesting to see if Daxx is able to stabilize MdmX in the same way
as it does for Mdm2. It would also be informative to examine if Daxx is able to interact
with MdmX and whether this interaction is affected by DNA damage.
During the course of this study, a report discovered many additional sites of
ATM-mediated phosphorylation on Mdm2 (Cheng, Chen, et al, 2009). We obtained
Mdm2 mutants from this group that were either phosphorylation-resistant (Mdm2 6A) or
phospho-mimics (Mdm2 6D). Preliminary data indicated that Daxx could enhance the
stability of Mdm2 6A, but not Mdm2 6D. This is in agreement with our findings that
phosphorylation is able to interrupt the interaction between Daxx and Mdm2. It would be
informative to see if phosphorylation events on both Daxx and Mdm2 act in a synergistic
manner to activate p53, as the effect of the Daxx mutant alone was quite modest.
Additionally, the binding between Daxx and Hausp is interrupted upon DNA damage;
however, use of the Daxx S564A mutant does not prevent the dissociation of Daxx and
Hausp (unpublished results from Dr. Jun Tang), indicating that an unidentified
phosphorylation event on Hausp may be regulating this interaction. Determining if this
phosphorylation occurs due to ATM signaling would provide yet another mode of p53
regulation through the Daxx-Mdm2-Hausp complex.
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Mdm2 activity cannot solely be controlled by Daxx, but also by the ARF tumor
suppressor. ARF upregulation is often induced by the overexpression of oncogenes
such as activated Ras and c-Myc (Groth, Weber, et al, 2000; Zindy, Eischen, et al,
1998). It is known that ARF can inhibit the E3 ubiquitin ligase activity of MDM2, resulting
in p53-mediated apoptosis or cell cycle arrest (Kamijo, Weber, et al, 1998; Pomerantz,
Schreiber-Agus, et al, 1998; Stott, Bates, et al, 1998). ARF can also interact with Daxx
and induce its nucleolar translocation in addition to enhancing the SUMOylation and
ubiquitination of Daxx, without affecting its protein levels (Ivanchuk, Mondal, and Rutka,
2008). Ivanchuk, et al showed that Daxx expression interferes with the ability of ARF to
induce Mdm2 SUMOylation, thereby increasing the ubiquitination of Mdm2 and allowing
for p53 activation; it is thought that inhibition of Mdm2 SUMOylation is required to
upregulate Mdm2 self-ubiquitination (Lee, Lee, et al, 2006). The study by this group
suggests that the interaction between ARF and Daxx influences the post-translational
modifications of Mdm2 that are required to inhibit Mdm2-mediated p53 ubiquitination
during cellular stress. It is possible that ARF is able to disrupt the Daxx-Mdm2-Hausp
complex upon induction of stress signals via binding to Daxx and Mdm2 separately and
mediating their post-translational modifications. There is a previously established ARFinducible U2OS cell line that we could use to test how induction of ARF affects binding
between components of the Daxx-Mdm2-Hausp complex. Moreover, it would be
interesting to see if ARF is able to modify or interact with Hausp, thereby modulating the
activity of Hausp toward Mdm2. Elucidating if ARF can affect the Daxx-Mdm2-Hausp
complex would demonstrate that this complex is regulated by various cellular stresses
using different mechanisms, denoting this complex as a central regulator of p53 activity.
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Daxx as a Novel Molecular Chaperone
Daxx has been implicated in a variety of cellular functions since its discovery.
This study uncovers yet another potential biological role of Daxx as a molecular
chaperone, which may serve as a way to unify the diverse functions of Daxx. Our in vitro
studies demonstrate that Daxx can refold misfolded substrates; however, it has minimal
activity toward larger aggregates. Consistent with the in vitro results, we saw that Daxx
could decrease the protein levels of insoluble luciferase and preferentially bound to heatshocked luciferase. Additionally, Daxx showed refolding activity toward p53 both in vitro
and in vivo.
Our results indicate that the PAH2 and acid-rich domains of Daxx are important
for its activity. Although, it has previously been reported that the domains denoted as
paired amphipathic helical domains are a misnomer (Escobar-Cabrera, Lau, et al, 2010),
we still feel that the crude structural boundary we have used defines a domain important
for the activity of Daxx. In addition, we found that the acid-rich region of Daxx imparts
activity to misfolded luciferase. Both regions are well conserved through evolution in
larger mammals (Figure 5.2). These observations support an evolutionarily conserved
function for these two domains. The creation of point mutants or small deletion mutants
within the conserved areas of the PAH2 and/or D/E domain would allow us to test
exactly which residues of Daxx are interacting with misfolding species. In fact, it is
known that the binding site for p53 lies within the D/E region of Daxx (Zhao, Liu, et al,
2004). It would be interesting to test if the aforementioned mutants would be able to
solubilize misfolded p53. Moreover, we should assay if the DaxxΔΔ mutant or the PAH2
and D/E domains alone can act toward p53 renaturation.
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Figure 5.2. Examination of evolutionary conservation of the PAH2 and D/E
domains in human Daxx.
Alignment of human Daxx (gi|48146287) with corresponding Daxx sequences from Bos
Taurus (gi|157278987), Mus musculus (gi|2253707), and Rattus norvegicus
(gi|18148939) for regions around PAH2 domain (157-260) (A) and D/E region (414-505)
(B). Alignment was done using using Clustal W2 (Goujon, McWilliam, et al, 2010; Larkin,
Blackshields, et al, 2007). Black arrowheads indicate boundaries of regions.
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In all of the in vitro experiments, Daxx was used without the addition of ATP. This
indicates that Daxx does not require energy to exert its refolding activity. The lack of
energy coupling seen in Daxx-mediated activity is in contrast to the energy requirement
for the traditional chaperones. While Daxx cannot suppress aggregation, and may in fact
accelerate aggregation during heat shock, it can still recover luciferase activity to a
greater proportion than when luciferase is alone or expressed with a canonical heat
shock protein (Figure 3.6). This, in combination with the observation that Daxx
accelerated denaturation of luciferase in vitro (Figure 3.4), suggests that Daxx can
promote a reaction that is contextually favorable, not one that is energy consuming. This
is consistent with the finding that Daxx preferentially binds to misfolded luciferase
substrates. It is important to note that while Daxx is unable to reactivate larger luciferase
aggregates in vitro, it is able to reactivate luciferase after heat shock in vivo when
luciferase should be in a mostly aggregated state (Parsell, Kowal, et al, 1994). Though
seemingly contradictory, this finding implies that either Daxx can promote the refolding of
the misfolded, not aggregated, luciferase during recovery or that it cooperates with other
chaperones to increase disaggregation.
Finally, we have shown initial evidence for a role of Daxx in the regulation of p53
distinct from what we have previously found (Tang, Qu, et al, 2006). The study by Tang,
et al also stated that Daxx does not affect the transcription of p53, thus the effect we are
seeing is most likely due to a post-transcriptional mechanism. We demonstrate that
Daxx can increase levels of p53 when Mdm2 is not present, which contradicts our
previous finding that Daxx is an indirect negative regulator of p53. We can reconcile
these two disparate ideas by the notion that Daxx is solubilizing p53 so that Mdm2 can
more easily target it for degradation or that Daxx is making the p53 ubiquitination sites
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more accessible to Mdm2 via its chaperone function. The possibility cannot be excluded
that since we used an Mdm2 null background, the effect we are seeing is not specific to
p53 but an artifact of Daxx being able to execute its chaperone function when Mdm2 is
not present, rather than participation in the Daxx-Mdm2-Hausp complex. A caveat of
these experiments is that we were unable to correlate increased p53 expression with
higher p53 transactivation. We attempted to perform reporter assays using the p53responsive genes p21, Noxa, and Bax; however, we saw the repression of their
transcription upon Daxx overexpression. This is expected, as Daxx is known to be a
transcriptional repressor that can inhibit p53 transactivation (Gostissa, Morelli, et al,
2004), preventing us from being able to separate the effects of Daxx on transcription
from those of p53 on transcription.
Future Directions
We have discovered a heretofore unknown role for Daxx in protein folding. It is
clear that Daxx does not act like a traditional chaperone in that it is not able to prevent
aggregation nor is it able to promote disaggregation. Rather, Daxx behaves more as an
unfoldase or refoldase, favoring the thermodynamically more amenable form of a
stressed substrate. We have shown both in vitro and in vivo evidence for this
phenomenon but many questions remain as to how Daxx exerts its chaperone activity.
First, we have unexpectedly observed that Daxx can accelerate the denaturation
of proteins during heat shock. There may be precedent for this activity as studies show
that the activity of the Hsp70 chaperones can be that of an unfoldase (Sharma, De los
Rios, et al, 2010; Slepenkov, and Witt, 2002). Hsp70 acts an ATP-fueled polypeptide
unfoldase that acts upon misfolded monomeric substrates and traps them in an unfolded
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state, after which they are released from Hsp70 and allowed to spontaneously refold
without the aid of a chaperone or input of energy (Sharma, De los Rios, et al, 2010).
However, this system requires the input of energy for the first unfolding step, albeit the
energy cost is quite low (about 5 molecules of ATP for unfolding of one polypeptide of
luciferase). Following this study, the same group discovered that certain chaperonins
(GroEL-GroES, in this case) possess the same ability to unfold denatured substrates
and release them into solution for spontaneous folding (Priya, Sharma, et al, 2013).
When GroEL was applied to denatured rhodanese monomers, it was able to efficiently
unfold rhodanese in an ATP-independent manner. Subsequent spontaneous refolding
was seen as in the case of Hsp70; however, fully efficient refolding required the addition
of ATP and GroES. It is tempting to postulate that Daxx may act in a similar way in that
when luciferase becomes denatured it forms misfolded species that are rapidly unfolded
by Daxx, as demonstrated by the acceleration of loss of activity during heat shock. After
the stress is removed and/or luciferase has reached a state from which it can be
refolded, it is released from Daxx and transferred to another chaperone or is able to
spontaneously refold, as seen by the reactivation of luciferase during the recovery phase
(Figure 3.6). To determine if Daxx is an unfoldase, we can apply similar methods used in
the two studies discussed above where they use Thioflavin-T (ThT) binding to β-sheet
structures as a quantifiable measure for misfolding, unfolding, and refolding. Ideally, ThT
binding should be highest in the initially denatured substrate, should be lowest upon
addition of the chaperone, and increase, concomitantly with an increase in activity of the
substrate, during refolding.
Second, we would like to determine how Daxx recognizes misfolded substrates
via the PAH2 and D/E domains. A deeper analysis of the structure of Daxx reveals many
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disordered regions (Figure 5.3) as predicted by the Predictor of Naturally Disordered
Regions (PONDR) VL-XT (Li, Romero, et al, 1999; Romero, Obradovic, and Dunker,
1997; Romero, Obradovic, et al, 2001). The PAH2 and D/E domains both have predicted
highly disordered regions. It is known that intrinsically disordered regions in small heat
shock proteins are involved in the binding of misfolded substrates (Haslbeck, Ignatiou, et
al, 2004; Jaya, Garcia, and Vierling, 2009; Stromer, Fischer, et al, 2004). Further, a
recent study shows that San1, a yeast nuclear ubiquitin ligase involved in protein quality
control, is able to bind to a variety of disparate substrates via its disordered N- and Cterminal domains. These domains contain highly conserved small segments of order,
which serve as substrate-recognition sites (Rosenbaum, Fredrickson, et al, 2011). They
speculate that these disordered regions allow San1 a conformational flexibility enabling it
to bind to many different misfolded substrates. It is possible that Daxx is working through
a similar manner, which would not only explain the diverse array of Daxx binding
partners, but also its ability to bind to misfolded substrates (Figure 3.13-14). The loss of
the PAH2 and D/E domains may lead to reduced plasticity of Daxx and may explain why
neither domain alone has activity, but together they are able to renature misfolded
substrates. To test this, we could create many small deletions within Daxx and assess if
the deletion mutants have any effect on association with misfolded substrates. PONDR
predicts possible binding sites as dips in disorder; thus, it would be informative to
correlate any binding-defective mutants with regions in the PONDR plot that may be
potential binding regions.
Third, determining if the acid-rich region of Daxx defines a new function for
polyanionic entities would be enlightening as, to our knowledge, no theory has been
proposed that puts forth a biochemical function for highly acidic regions within proteins.
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Figure 5.3. Daxx contains regions of disorder.
Disorder prediction of Daxx was run using PONDR (http://www.pondr.com). PAH2
domain lies between residues 157-260. D/E region is between residues 414-505.
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Besides the ability to confer conformational flexibility as discussed above, a polyanionic
stretch within a protein may have a more defined function. It has previously been shown
that proteins containing polyanionic regions have chaperone activity, and that these
effects are specific to anionic regions, as polycationic species do not have such activity
in vitro (Jones, Yazzie, and Middaugh, 2004; Rentzeperis, Jonsson, and Sauer, 1999).
Further, some of the smaller heat shock proteins have flexible C-terminal regions that
are rich in acidic amino acids, which when mutated, lead to reduced activity (Edwards,
Kueltzo, et al, 2001; Narberhaus, 2002). Members of both the large and sHsp protein
families interact with polyanions such as nucleic acids and tubulin (Korber, Zander, et al,
1999; Koyasu, Nishida, et al, 1986). It is conceivable that Daxx is part of a family of acidrich domain containing proteins that share a similar function in terms of chaperone
activity. Preliminary bioinformatics analysis done by another graduate student in the lab,
Aaron Stonestrom, indicated that there are about 100 proteins in the human genome
that contain 40 acidic amino acids within a 100-residue window. It would be informative
to test if swapping acidic regions of those proteins with that of Daxx would still allow
Daxx to retain its chaperone activity, providing evidence for the generality of the
polyanionic-dependence of this activity. A similar analysis was done for the PAH2
domain; however, no other proteins contained a homologous region signifying that this
region is very unique and specific to Daxx.
We would also like to know if the recently determined histone chaperone function
of Daxx is related to the protein folding activity we have discovered. So far, the role of
Daxx as a histone chaperone has been defined as its ability to deposit the histone
variant H3.3 at telomeric or pericentric chromatin in cooperation with ATRX (Drane,
Ouararhni, et al, 2010; Elsaesser, and Allis, 2010; Lewis, Elsaesser, et al, 2010). A
115

recent study has crystallized the structure of the histone-binding domain of Daxx bound
to an H3.3-H4 dimer (Elsasser, Huang, et al, 2012). They determined several singlepoint alanine mutations that led to disruption of the Daxx-H3.3-H4 complex: Ser220,
Tyr222, Arg251, Phe317, Arg328, Asp331, and Asp349. The first three residues lie
within the PAH2 domain and none of the point mutants are found in the D/E domain. It
would be interesting to know how the structure of the PAH2 domain is altered in the
presence of these mutations and if these mutations affect the chaperone activity of
Daxx. If so, this could be a novel mode of histone chaperone activity by Daxx toward
H3.3. Related to the histone chaperone activity of Daxx, mutations in Daxx are
frequently found in PanNETs, often leading to an ALT phenotype. Two of these
mutations, E465X and E448X are found in the D/E region and lead to nonsense
mutations. Some of the other identified mutations lead to nonsense, missense, or indel
mutations (Jiao, Shi, et al, 2011). It would be very intriguing to test these different
mutations and their folding activity toward luciferase. If they have diminished ability to
reactivate denatured substrates, this may provide a connection between histone
chaperone activity, protein folding, and potentially tumorigenesis.
The molecular chaperones of the heat shock family are so named because they
are responsive to heat shock and other cellular stresses (Hartl, Bracher, and HayerHartl, 2011). Thus, the question arises if Daxx is also sensitive to cellular stress. Indeed,
Daxx has previously been shown to be responsive to heat shock in that its SUMO-2
conjugation status is increased by 24-fold upon heat shock (Golebiowski, Matic, et al,
2009). Our results support the ability of Daxx to respond to thermal stress in that it has a
preference for associating with non-native substrates formed by heat shock in vivo
(Figure 3.13-14). Whether or not this preference is dependent upon the SUMOylation
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status of Daxx would be very interesting to determine. Currently, there is no clear
consensus as to the main function of SUMOylation in the cell, though it has been shown
to be important for transcriptional regulation, protein stability, and apoptosis
(Golebiowski, Matic, et al, 2009). The use of SUMO-modified Daxx in vitro may enhance
the activity of Daxx toward denatured substrates if SUMOylation is important for the
activity of Daxx. To corroborate these results in vivo, use of Daxx mutants that are
unable to be SUMOylated would allow us to determine the SUMO-dependence of Daxx
chaperone activity.
Finally, we have discovered that Daxx is able to solubilize misfolded p53. Our lab
has previously found that Daxx can enhance the E3 ubiquitin ligase activity of Mdm2
toward p53 both in vitro and in vivo (Tang, Qu, et al, 2006). It is possible that Daxx is
promoting the oligomerization of p53, an activity important for the ability of Mdm2 to
ubiquitinate p53 (Maki, 1999). To test this, we could incubate Daxx with purified p53 and
determine the oligomerization state of p53 via gel filtration. Determining if deletion of the
PAH2 and/or D/E domain in in vitro ubiquitination reactions affects Mdm2 E3 activity
may suggest a link between the protein folding activity we have found with the ability of
Daxx to enhance the E3 activity of Mdm2 toward p53. Additionally, it is possible that the
phosphorylation event we have found for Daxx (see chapter two) not only leads to Mdm2
destabilization, but also allows Daxx to alter the conformation of p53 so that it can be
better targeted by Hausp or other p53 activating proteins. This could be tested via the
use of conformation-specific antibodies in the presence or absence of Daxx and with or
without DNA damage. To address more therapeutic consequences of Daxx activity, it
would be interesting to apply Daxx to conformational p53 mutants. Previous work has
indicated that some p53 mutations found in human tumors create aggregation-prone
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mutant p53 that co-aggregates with wild-type p53, leading to dominant-negative effects
on wild-type p53 (Xu, Reumers, et al, 2011). It is possible that Daxx is able to relieve this
co-aggregation, at least insofar as wild-type p53. We have tested p53 R175H, an
aggregation-prone mutant in vitro using mammalian-purified Daxx. We saw that Daxx
was indeed able to solubilize mutant p53; however, we have not corroborated this result
using Daxx purified from bacteria. To determine the in vivo relevance of these findings,
experiments could be performed where we co-express Daxx and a p53 mutant and
fractionate the cell lysate on native gels to visualize the oligomerization state of p53. It is
important to note that the aggregation-prone p53 mutants generally localize in the
cytoplasm, while Daxx is a predominantly nuclear protein. Thus, it would be necessary to
either prevent nuclear import of Daxx or mutate putative nuclear localization signals
within Daxx so that it can associate with cytoplasmic p53.
In summary, we have demonstrated that Daxx has the ability to refold misfolded
proteins both in vitro and in vivo. This function may also provide a biochemical basis to
unify the many functions of Daxx. Indeed, Daxx has an extensive list of binding partners,
reminiscent of how Hsp70 can interact with the entire spectrum of heat-denatured
proteins in E. coli (Mogk, Tomoyasu, et al, 1999)It is possible that Daxx acts as a
general mediator of protein folding for a wide array of proteins; however, many questions
remain unanswered as to the mechanism and physiological relevance of the protein
folding activity of Daxx. Finding the answers to these questions would have great
implications for protein quality control in the cell by determining how misfolded folded
proteins are reactivated, by potentially defining a new class of chaperones containing
acid-rich regions important for their activity, and by expanding histone chaperone activity
to include protein folding. Additionally, determining if Daxx can solubilize pathogenic
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forms of p53 would add another layer of complexity to p53 regulation by Daxx and
provide a potential therapeutic target in cancer.
The Role of Daxx in Cdk6 Regulation
The cell cycle is an intricately controlled process and its regulation is necessary
for the proper proliferation and growth of cells. Thus, understanding how its major
effectors are controlled is important for the development of therapeutics as mutations in
genes encoding the Cdks and cyclins have been observed in cancer (Vermeulen, Van
Bockstaele, and Berneman, 2003). The present study showed that Daxx is able to affect
the protein and mRNA levels of the cyclin D associated Cdk, Cdk6. We showed that
Daxx depletion leads to lower levels of Cdk6; however, there was no robust effect on
cellular proliferation. The effect of Daxx on Cdk6 was specific for Cdk6 as other cell
cycle markers tested showed no difference in protein level upon Daxx knockdown. The
effect on Cdk6 was also seen in a variety of cancer and primary cell types, suggesting
that this was a not cell-type specific phenomenon.
A limitation of the current study was the presence of Cdk4 in all of the cell lines
tested. Cdk4 and Cdk6 are generally thought to play redundant roles within the cell,
though their mutual compensation has been controversial (Berthet, and Kaldis, 2006).
There is only a mild phenotype associated with Cdk6 -/- mice but the phenotype is
exacerbated in Cdk6 -/-; Cdk4 -/- embryos, as they die during development (Malumbres,
Sotillo, et al, 2004), suggesting that Cdk4 may play a partially compensatory role when
Cdk6 is not present. Thus, a more dramatic proliferative phenotype may be observed if
we use cells that lack Cdk4 and then silence Daxx. If we see a strong decrease in
proliferation, this would suggest that Daxx is a major regulator of Cdk6 and that this
regulation has consequences for cellular proliferation.
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It is also important to note that other studies have determined that loss of Daxx
leads to perturbations in normal mitotic cycling (Giovinazzi, Lindsay, et al, 2012;
Gongora, Stephan, et al, 2001; Kwan, Lau, et al, 2013; Pan, Yi, et al, 2013). Our results
indicate that silencing of Daxx does not lead to changes in the cell cycle profile (Figure
4.11). Most of these studies observed very minute changes in cell cycle progression that
were cell-type specific. It is possible that our conditions were not sensitive enough to
elicit detectable changes in the cell cycle upon Daxx depletion.
Future Directions
The main challenge for us is to determine a physiologically relevant setting in
which to study the regulation of Cdk6 by Daxx. We could examine the ability of Daxx to
regulate Cdk6 in thymocytes as Cdk6 is thought to be the primary kinase that initiates
pRb phosphorylation in thymocytes, due to its preferential expression in hematopoietic
cells (Meyerson, Enders, et al, 1992; Meyerson, and Harlow, 1994). Consistent with this
finding, Cdk6 -/- mice display defects in thymus development and reduced thymic
cellularity (Malumbres, Sotillo, et al, 2004). Expanding upon these findings, another
group determined that Cdk6 is required for Notch-dependent T-cell development and
differentiation as cells without Cdk6 display maturation defects (Hu, Deshpande, et al,
2009). Thus, it would be interesting to determine if Daxx regulates Cdk6 in thymocytes.
Furthermore, Cdk6 downregulation has been implicated in the differentiation of various
cell types including osteoblasts (Ogasawara, Kawaguchi, et al, 2004) and leukemic cells
(Matushansky, Radparvar, and Skoultchi, 2003). In these instances, Cdk6 expression
inhibits differentiation and downregulation of Cdk6 is necessary for the cells to enter
terminal differentiation steps. It would be informative to analyze Daxx levels during the
differentiation of these cells; if we can observe a concomitant loss of Daxx expression,
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perhaps prior to loss of Cdk6 expression, we may be able to form a link between the
importance of the regulation of Cdk6 by Daxx and cellular differentiation. Interestingly,
Daxx has been shown to inhibit muscle differentiation via repression of the transcription
factor, E2A (Gupta, Hou, et al, 2009); E2A inhibits Cdk6 gene expression (Schwartz,
Engel, et al, 2006). This suggests a model whereby inhibition of E2A by Daxx allows for
Cdk6 activation and inhibition of cell differentiation. We should determine the E2Adependence of the Daxx effect on Cdk6 via silencing of E2A in cells.
We were unable to go far beyond mRNA analysis (Figure 4.8) and promoter
binding (Figure 4.9) to determine the role of Daxx in Cdk6 transcription. Since Daxx is
not known to contain a DNA binding domain, it is likely that Daxx is indirectly binding to
the Cdk6 promoter. There are binding sites for NF-κB, Ets, Sp1, and p300 within the
Cdk6 promoter (Cram, Liu, et al, 2001). Daxx is known to modulate the transcriptional
activity of NF-κB and Ets; thus, it would be informative to test if experimental reduction of
either transcription factor would abrogate the transcriptional regulation of Daxx toward
Cdk6.
Another interesting question is if Daxx works in cooperation with ATRX to control
Cdk6 transcription. Importantly, U2OS cells do not contain endogenous ATRX (Niforou,
Anagnostopoulos, et al, 2008), yet we were able to observe a decrease in Cdk6 levels
upon Daxx knockdown (Figure 4.3A), suggesting that Daxx may not be completely
dependent upon ATRX for its activity. It is still possible that in other cell lines, Daxx and
ATRX work together to repress a subset of genes, one of which may be Cdk6. Daxx and
ATRX are known to form a heterochromatin-remodeling complex, which is able to
regulate transcription often via recruitment to sequence-specific transcription factors that
bind to these promoters (Tang, Wu, et al, 2004; Xue, Gibbons, et al, 2003). When ATRX
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is tethered to DNA, it is able to repress transcription. However, ectopic expression of
Daxx alleviates ATRX-mediated transcriptional repression via sequestration of ATRX to
PML-NBs by Daxx (Tang, Wu, et al, 2004). It is possible that the effect we are seeing is
partially ATRX-dependent and that ATRX can also inhibit Cdk6 transcription.
Theoretically, when Daxx is not present, ATRX is able to repress transcription of Cdk6;
however, when Daxx is present, ATRX is sequestered to PML-NBs, thereby alleviating
the transcriptional repressive effects of ATRX toward Cdk6.
Concluding Remarks
This dissertation has examined several biological functions of Daxx. We have
shown that Daxx is a novel substrate of ATM and that phosphorylation of Daxx by ATM
impairs the association of Daxx and Mdm2, allowing for p53 activation. Second, we have
shown that, depending upon the cellular context, Daxx has the ability to promote the
denaturation or renaturation of a protein. Finally, we have identified a new transcriptional
target of Daxx: Cdk6, a cyclin D associated kinase involved in both cellular proliferation
and differentiation. While these findings further our knowledge regarding the intracellular
activities of Daxx, they also raise many questions as to how and when Daxx exerts these
activities. Creation of a conditional Daxx -/- mouse may help answer some of these
questions if defects in cellular functions are found and/or if these defects occur in a
tissue-specific manner. Additionally, elucidation of the crystal structure of Daxx would
allow us to determine how Daxx preferentially binds to misfolded species and where
exactly this interaction occurs.
Its demonstrated flexibility in response to different cellular conditions forces us to
question why the role of Daxx would be so multifunctional. It is possible that Daxx can
mediate a set of diverse responses depending upon the needs of the cell, providing a
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potential explanation for its extensive list of interacting partners. The novel role of Daxx
in protein folding may also provide a biochemical mechanism to unify all these functions
of Daxx in that Daxx can assist a wide range of proteins to reach their native
conformation; this may be why Daxx is involved in such disparate activities. Further,
Daxx has been implicated in a few instances of human disease; however, the role of
Daxx in the pathogenesis of disease remains unclear. Understanding the dynamic
nature of Daxx will help us not only to understand the basic regulation of many biological
processes, but may also provide a basis for establishing Daxx as a valid therapeutic
target.
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